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Abstract 
It is estimated that half the world’s population is infected with Helicobacter pylori in the stomach. Chronic H. pylori 
infection can lead to peptic ulcer disease or gastric cancer, but only in a sub-population of infected individuals. 
Eradication of the bacteria with antibiotic treatment can be successful, but the emergence of antibiotic resistant 
strains of H. pylori is a problem in areas endemic with H. pylori infection. A mucosal vaccine would have the 
potential for boosting the immune response to H. pylori, preventing and thus reducing the prevalence of the 
infection. In spite of decades of intense research, no vaccine has yet been found to be effective against H. pylori 
infection in humans. The work in this thesis aimed to evaluate the impact of varying the adjuvant and route of 
mucosal vaccinations on the gastric immune response and protection against H. pylori infection in a mouse model. 
In particular, the role of cytokines induced by H. pylori infection was evaluated, with an objective to separate the 
protective and pathogenic immune response in the stomach. In the first part of the thesis, the adjuvant effect of a 
detoxified mucosal adjuvant based on the E. coli heat labile toxin LT, double mutant heat-labile toxin 
R192G/L211A (dmLT) addressed the differences if any, in immune responses and protection against H. pylori 
infection after sublingual (SL; under the tongue) and intragastric (IG) route of vaccination with H. pylori antigens 
and the prototype mucosal adjuvant cholera toxin (CT). And finally, using gene knockout mice and neutralizing 
antibodies, the impact of cytokines IFN and IL-17A on bacterial load and immune responses was addressed.  
 
Sublingual vaccination with H. pylori antigens and dmLT as an adjuvant was efficient in reducing the bacterial load 
in the stomach of mice, similar to when using the potent adjuvant CT, which is highly toxic in humans. Compared to 
infected unvaccinated mice, sublingual vaccination with dmLT enhanced stomach IFNγ and IL-17A secretion and 
proliferative responses to H. pylori antigens in mesenteric lymph nodes and spleen. Furthermore, we could show that 
there was a tendency for the sublingual route to be more efficient than the intragastric route of vaccination in 
reducing the bacterial load in the stomach. And that the sublingual route of vaccination enhanced both IFN and IL-
17A responses in the draining lymph nodes compared to unvaccinated mice. Studies on the role of individual 
cytokines in vaccine-induced responses revealed that after sublingual vaccination, IFN knockout (IFNγ-/-) mice 
were protected against H. pylori infection and had elevated IL-17A production and lower inflammation scores in the 
stomach compared to vaccinated wild-type mice. Furthermore, neutralization of IL-17A in sublingually vaccinated 
IFNγ-/- mice abrogated protection against H. pylori infection. As IL-17A was found to be important for vaccine-
induced protection, we next examined the mechanisms for induction and maintenance of IL-17A after sublingual 
vaccination by studying the role of cytokines IL-1β and IL-23. Our results show that after sublingual vaccination, 
IL-23, but not IL-1β, deficient mice were protected against H. pylori infection. Gastric IL-17A responses could not 
be induced after challenge in the absence of IL-1β, but could be maintained in the absence of IL-23.   
 
In summary, we report that dmLT can be considered as a strong candidate mucosal adjuvant for use in a H. pylori 
vaccine in humans particularly when administered via the sublingual route. Furthermore, we show that IL-17A 
might contribute to protective immune responses, while IFNγ may promote inflammation. The results presented in 
this thesis will facilitate the design and administration of a vaccine against H. pylori infection in humans.  
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ABBREVIATIONS 
 
ADP  Adenosine diphosphate 
APC  Antigen presenting cells 
CagA  Cytotoxin associated gene A 
CagPAI Cag Pathogenicity Island 
cAMP  cyclic adenosine monophosphate 
CFU  Colony forming units 
CLN  Cervical lymph nodes 
CT  Cholera Toxin 
CTA  Cholera Toxin A subunit 
CTB  Cholera Toxin B subunit 
CTL  Cytotoxic T lymphocyte 
DC  Dendritic cell 
dmLT  double mutant heat-labile toxin  
HpaA  H. pylori adhesion A 
IFNγ  Interferon gamma 
IG  Intragastric 
ILC  Innate lymphoid cells 
IL  Interleukin 
IN  Intranasal  
i.p.  intraperitoneally 
LT  Heat-labile toxin 
LTA  Heat-labile toxin A subunit 
LTB  Heat-labile toxin B subunit 
LMIC  Low and middle income countries  
MHC  Major Histocompatability Complex 
MLN  Mesenteric lymph nodes 
NAP  Neutrophil Activating Protein 
NLR  Nod-like receptor 
Nod  Nucleotide-binding Oligomerization Domain 
PAMP  Pathogen associated molecular pattern 
PRR  Pattern recognition receptor 
SL  Sublingual 
TGFβ  Transforming growth factor beta 
Th  T helper 
TLR  Toll-like receptor 
TNFα  Tumor necrosis factor alpha 
Treg  Regulatory T cell 
VacA  Vacuolating cytotoxin A
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Introduction 
History and Epidemiology of Helicobacter pylori infection 
Helicobacter pylori was first discovered by Warren and Marshall in 1983 when they regularly 
found spiral shaped bacteria in biopsies from patients with gastritis and peptic ulcer disease. 
Later, Marshall cultured the bacteria ex-vivo and, by ingesting the spiral shaped bacilli, proved 
that it is the major cause of chronic inflammation in the stomach [1]. This discovery gave new 
insights into the mechanisms of gastric disorder in subsets of infected individuals with gastritis, 
acid reflux disease and peptic ulcers, which could now be attributed to H. pylori infection. Since 
the discovery of H. pylori, the pathogeneses of associated inflammatory and malignant diseases 
have been intensively investigated. 
 
Approximately half of the world´s population is infected with H. pylori in the stomach. H. pylori 
infection is most prevalent in the low and middle income countries (LMIC) in which it is 
estimated that 80-90% of the population are infected while the prevalence of the infection has 
decreased in developed countries in which less than 40% are infected [172]. H. pylori infection 
in LMIC is typically acquired during early childhood [63, 136]. The transmission of H. pylori 
occurs most often via the fecal-oral route or the oral-oral route in crowded and unsanitary living 
conditions [75, 169]. Whether contaminated environmental and drinking water can be a reservoir 
for the bacteria and the source for new infections has been debated. This is due to fact that it has 
been extremely difficult to detect H. pylori DNA in environmental and drinking water samples 
[91]. Transcriptionally active bacteria were instead found in, for example, vomitus and fecal 
samples of H. pylori -infected individuals with ETEC diarrhea, supporting the proposed oral-oral 
or fecal-oral routes of transmission [29, 76, 91, 171]. 
 
Helicobacter pylori colonization and clinical aspects 
H. pylori colonize the human stomach and duodenum and reside in the gastric mucus layer and 
also in close proximity to the epithelium [34, 63, 226-227]. The bacteria colonize mainly the 
corpus and antrum regions of the stomach and in areas of gastric metaplasia in the duodenum 
[208, 227]. H. pylori have evolved mechanisms of protection against the gastric acid in the 
human stomach. For example, the colonization factor flagellae allow for rapid movement 
through the mucus, while secreted urease neutralizes the low pH, and adherence factors, for 
example, BabA and SabA1 help the bacteria bind to gastric epithelial cells [108, 138, 166, 187]. 
Other putative virulence factors are, for example, cytotoxin-associated gene A (CagA), 
vacuolating cytotoxin protein A (VacA), neutrophil activating protein (NAP) and the putative H. 
                                                            
1 BabA: blood group antigen-binding adhesion; SabA: sialic acid-binding adhesin 
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pylori adhesion A (HpaA) [152, 187, 189]. Some of these components facilitate the evasion and 
dampening of the host immune response [189]. CagA is encoded by the cag pathogenicity island 
(CagPAI) gene cluster, which is believed to encode many more virulence factors. CagA is 
injected into the cytoplasm of gastric epithelial cells via the type IV secretion system, which is 
also encoded in the CagPAI [187]. Translocation of CagA into the cytoplasm induces gastric 
epithelial cell changes and pro-inflammatory immune responses via activation of the nuclear 
factor kappa B (NF-κB) pathway and binding to intracellular nucleotide-binding oligomerization 
domain-containing protein 1 (Nod1) receptors [156]. Translocation of CagA also results in 
CXCL8 production by epithelial cells [97]. VacA can initiate the formation of trans-membrane 
pores and induce vacuolization and apoptosis of epithelial cells [41-42]. In addition, it has been 
proposed that VacA also disturbs antigen processing and presentation by antigen presenting cells 
(APC) and inhibits T cell proliferation [41]. NAP secreted by the bacteria attracts neutrophils 
and induces the production of IL-6, CXCL8, IL-12 and IL-23 from monocytes, mast cells and 
neutrophils in vitro [16, 64, 153, 191]. HpaA is a surface lipoprotein and a putative adhesion that 
has been shown to be highly conserved amongst strains of H. pylori [93, 165]. HpaA has also 
been shown to be a colonization factor in mice [164]. Additionally, studies in mice have shown 
that immunization with recombinant or purified HpaA can confer protection against H. pylori 
infection and might be a promising antigen to include in a H. pylori vaccine together with urease 
[33, 164]. 
 
H. pylori infection causes gastritis in all infected individuals but only a subset of those infected 
develop clinical symptoms [108]. About 10-15% of chronically infected individuals develop 
symptoms e.g. dyspepsia and peptic ulcers and 1-2 % have an increased risk of developing 
gastric cancer [63]. The so-called “triple therapy” is a treatment regimen against H. pylori 
infection in symptomatic individuals. It consists of combination of two antibiotics taken with a 
proton pump inhibitor two times a day for two weeks [73]. In spite of good eradication rates and 
cure of symptoms related to the infection, epidemiological studies have reported that a previous 
infection does not protect against reinfection after antibiotic treatment [82, 114, 137]. 
Furthermore, the emerging antibiotic resistance among H. pylori strains and poor patient 
compliance make the antibiotic eradication treatment unsuitable particularly in LMIC where H. 
pylori are highly prevalent and reinfections common. For these reasons, vaccination has been 
suggested as an approach for the control of H. pylori infection and disease [158].  
 
Developing vaccines against pathogens that cause chronic infections for e.g. HIV, malaria and 
tuberculosis has proven to be challenging and H. pylori is no exception in this regard [186]. The 
main hurdle in the development of a vaccine against H. pylori infection has been the selection of 
appropriate antigens, mucosal adjuvant and route of immunization to induce immune responses 
strong enough to eradicate the infection. Much basic knowledge about H. pylori and its 
interaction with the human host is now known, which can help in the design of a vaccine, some 
of which are discussed below [29, 76, 91, 171]. 
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Immune responses to Helicobacter pylori 
Innate immune responses 
Most of the bacteria reside in the mucus layer and occasionally some bacteria will relocate close 
to the epithelial layer and bind to host cells [17]. The innate response is initiated by the binding 
of bacteria to gastric epithelial cells. The pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs) and the Nod-like receptor (NLR) recognize pathogen-associated molecular 
patterns (PAMPs) on the bacteria [189]. TLRs and NLRs are present on many cell types such as 
epithelial cells, macrophages, dendritic cells (DCs) and lymphocytes. It has been suggested that 
H. pylori flagellin and lipopolysaccharide (LPS) may escape from being recognized by TLR5 
and TLR4 respectively, but that instead intact H. pylori bacteria may be recognized via TLR2 
and thereby initiate the NF-κB pathway and consequent pro-inflammatory response [140, 178]. 
In mice it has been shown that H. pylori DNA is recognized by intracellular TLR9 in DCs and 
that the adaptor signaling molecule MyD88 is essential for cytokine responses [178]. 
Peptidoglycan can be translocated together with CagA into the host cell and recognized by the 
intracellular nuclear oligomerization domain 1 (Nod1) which will also lead to NF-κB activation 
[222]. Triggering of, for example, Nod1 initiates the assembly of the inflammasome and 
eventually the secretion of pro-inflammatory molecules such as IL-1β (discussed below) [140].  
 
The H. pylori bacterial components, for example, virulence factors and colonization factors 
binding to gastric human epithelial cells, cause activation via TLRs and NLRs leading to a pro-
inflammatory cascade in the stomach that involves the secretion of IL-1β, IL-2, IL-6, CXCL8 
and tumor necrosis factor alpha (TNFα) [43, 107]. A major cause of influx of innate cells is the 
triggering by H. pylori of gastric epithelial cells to produce high concentrations of CXCL8 which 
acts as a chemoattractant for neutrophils [44]. In infected individuals, the above-mentioned 
cytokines and chemokine CXCL8, together with transforming growth factor β (TGFβ) and IFNγ, 
can cause additional immune cell infiltration of neutrophils, macrophages, mast cells and NK 
cells to the gastric mucosa [24, 36, 122, 124, 228]. The immune cells recruited to the stomach in 
response to bacterial antigens further amplify the response, leading to continuous recruitment of 
immune cells to the stomach during chronic infection. 
 
APCs such as macrophages or DCs can phagocytose the bacteria and their components and 
become activated and start to express chemokines and cytokines. The number of DCs is 
increased in the stomach of H. pylori infected individuals [27, 96]. In vitro studies have 
suggested that culturing DCs together with H. pylori and human natural killer (NK) cells can 
stimulate IFNγ secretion from the NK cells, suggesting a role for DCs in presenting the bacteria 
to NK cells [78]. Immature DCs are attracted to the stomach by the chemokine, CCL20, which 
binds CCR6 on DCs [40]. In the stomach of H. pylori-infected individuals, an increased CCL20 
gene expression and subsequent protein production, together with an influx of DCs has been 
reported [27, 231]. Similar increases in CCL20 and CCR6 can also be found in the stomach of 
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vaccinated mice post-challenge [67]. In addition, DCs may also bind directly to H. pylori via the 
DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) receptor [19]. Upon stimulation with H. 
pylori, immature DCs express CCR7 (binds CCL19/21 in the lymph nodes) and subsequently 
migrate to the draining lymph node to present antigen to T cells [22, 79]. Interestingly, in mice, it 
has also been shown that DCs have the ability to sample bacterial components directly in the gut 
lumen by extending dendrites through the epithelial layer [185]. This has also been suggested to 
occur in human H. pylori-infected stomach, in which intraepithelial DCs were observed and their 
dendrites extended through the epithelial layer and sampled the bacteria [157]. 
 
Macrophages can be activated by IFNγ which, early in infection, is mainly secreted by NK cells. 
Subsequently the activated macrophages in turn secrete more IFNγ together with microbicidal 
products, such as nitric oxide and reactive oxygen species and can also directly phagocytose the 
bacteria or infected neutrophils in the stomach [154]. H. pylori-infected individuals have 
increased levels of molecules associated with macrophage activation such as inducible nitric 
oxide synthase (iNOS) as well as the macrophage chemoattractant CCL3 [109, 177, 229]. 
Furthermore, mice infected with H. pylori have increased numbers of macrophages in the 
stomach and in the paragastric lymph nodes draining the stomach [14].  
Adaptive immune responses 
The adaptive immune response generally includes a humoral response with activation of B cells 
followed by production of antibodies together with activation of effector T cells and their 
recruitment to the local site of infection. Lymphocyte-attracting chemokines, such as CCL28, 
CXCL10, CXCL13 and CCL5 are produced in the infected gastric mucosa. In H. pylori-infected 
individuals, circulating peripheral blood lymphocytes express the homing receptor α4β7 and 
respond in vitro to H. pylori stimulation [176]. Activation of naïve lymphocytes occurs  in the 
lymph nodes when DCs present antigen on MHC class I (presentation to CD8+ T cells) or MHC 
class II (presentation to CD4+ T cells) together with the appropriate co-stimulatory molecules 
[28]. Presentation on MHC-I activates CD8+ T cells that differentiate into cytotoxic T 
lymphocytes (CTL) whereas presentation on MHC-II activates CD4+ T cells that differentiate 
into different T helper cell populations. CD4+ T helper (Th) cell responses are polarized, 
depending on the cytokines produced by the DCs presenting the antigens on MHC-II. During H. 
pylori infection, DCs can produce IL-1β, IL-6, IL-10, IL-4, IL-12 and IL-23 which will promote 
T helper 1 (Th1) or T helper 17 (Th17) cells and to a lesser extent T helper 2 (Th2) cells [27, 66, 
96].  
 
T cell responses  
H. pylori infection can activate both CD4+ and CD8+ T cells in humans, and subsequent IFNγ 
production which can be detected locally in the gastric mucosa [209]. The majority of T cells 
infiltrating the human stomach during chronic H. pylori infection are CD4+ and furthermore, of 
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Th1 phenotype, secreting IFNγ [203]. Th2 cells are mainly activated during extracellular 
parasitic infections such as helminth infection or to allergen exposure which would explain why 
only a minority of T cells are of the Th2 phenotype in H. pylori infection [203]. Interestingly, 
during recent years, another CD4+ effector T cell population has been investigated in H. pylori 
infection, namely Th17 cells, which are characterized by the production of the cytokine IL-17A 
(discussed below).  
 
In addition to the increase in number of T effector cells in the stomach during H. pylori infection, 
there is also an accumulation of CD4+CD25+ regulatory T cells (Tregs), which can dampen the T 
cell effector functions [129-130]. It has been shown that H. pylori-infected individuals have 
increased numbers of Tregs in the stomach that secrete IL-10 which subsequently dampens the 
secretion of CXCL8 by gastric epithelial cells in vitro [188]. Further IL-10 secreting Tregs may 
also suppress Th1 responses in vivo although this has not been shown in humans [50, 81, 188]. It 
has also been reported that DCs stimulated with H. pylori antigens in vitro induce proliferation of 
Tregs in humans [150]. This may explain the increase in frequency of Tregs found in the 
circulation and stomach of H. pylori-infected individuals [129, 188]. Studies in the H. pylori 
mouse model have shown that transient depletion or absence of Tregs results in decreased 
bacterial colonization in the stomach upon challenge with live bacteria but at the cost of 
exacerbated inflammation [179-180, 192]. Thus, by preventing excessive inflammation, Tregs 
were considered to be beneficial to the host during H. pylori infection. It has been proposed in 
chronic H. pylori infection in humans however that, the persistence of bacterial infection in the 
stomach followed by development of peptic ulcer disease may be due to the increase of Tregs in 
the tissue [188].  
 
Th1 responses  
As mentioned previously, H. pylori infection can induce DCs to secrete cytokines that will 
induce Th1 and Th17 responses. A CD4+Th1 response to H. pylori infection is initiated by DCs 
presenting the antigen on MHC-II molecule, followed by engagement of co-stimulatory 
molecules. Further, this will initiate the secretion of IL-12 which promotes Th1 responses and 
which has been found to be increased in the stomach of infected individuals [81]. The Th1 
response is defined by CD4+ T cell producing IFNγ and IL-2 which activate macrophages and 
induces T cell proliferation, respectively. In the context of H. pylori infection, IFNγ-producing 
cells have been shown to correlate with the severity of gastritis in infected human gastric mucosa 
[15, 85, 117, 124]. Similar results have been reported in mouse models in which a predominantly 
elevated Th1 response is correlated with more severe gastritis in the stomach [202].  
The recruitment of Th1 cells to the gastric mucosa during H. pylori infection occurs due to the 
expression of a number of specific chemokines. H. pylori bacteria can induce the expression of 
CCL5 and CXCL10 by human gastric epithelial cell lines and these chemokines have also been 
found to be elevated in the stomach tissue of H. pylori-infected individuals [15, 60, 105, 229]. In 
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human H. pylori infection, the CCL5 is secreted by epithelial cells, fibroblasts, CD8+ T cells and 
platelets and functions as a chemotactic molecule, mainly for T cells among other cells through 
binding to its receptors CCR1, CCR3, CCR4 and CCR5. Notably, CCR4 is found to be elevated 
in H. pylori-infected stomach tissue [20, 131]. In mice, CCL5 and CXCL10 are upregulated in 
the stomach after vaccination and challenge with live H. pylori [67].  
IFNγ 
IFNγ is produced by Th1, NK cells, CD8+ T cells, NK T cells, B cells and macrophages. IFNγ is 
a cytokine of diverse functions: it can induce isotype switching in B cells; it can also activate 
macrophages to enhance the ability to kill pathogens; it can induce apoptosis in epithelial cells; it 
plays a role in regulating antigen presentation, enhancing MHC-I- and MHC-II molecule 
expression on APCs; it can also upregulate the expression of CXCL10 and adhesion molecules in 
the endothelium and thereby increase leukocyte migration into the affected tissue [11, 15]. 
Furthermore, as mentioned previously, IFNγ is elevated in H. pylori-infected individuals and in 
infected mice [68, 203].  
 
Th17 responses  
In addition to IL-12, DCs may also produce IL-1β, IL-6, TGFβ and IL-23 in response to H. 
pylori [96]. The combinations of these cytokines are responsible for the induction and 
maintenance of the CD4+ Th17 response in mice and humans [39, 103, 219, 224]. However, 
although it has been shown that TGFβ has an important role in inducing Th17 responses in mice, 
its role in the induction of Th17 cells in humans is unclear. Further, it has been shown in humans 
that DCs stimulated with H. pylori antigens can induce IL-17A production from CD4+ T cells in 
vitro in culture [96]. Th17 cells are defined by secretion of the cytokines IL-17A, IL-17F, IL-21, 
and IL-22 in both humans and mice. Additionally IL-26 secretion and expression of the 
chemokine receptor CCR6 have also been observed in humans [4, 103]. Th17 cells are attracted 
to the stomach by the expression of tissue CCL20 binding to CCR6 on human Th17 cells. The 
Th17 cell secreting cytokines attract neutrophils, activate epithelial cells, generally amplify local 
inflammation, but also induce antibody secretion [151]. Importantly, Th17 cells are multi-
functional cells that produce cytokines involved in both pathogenicity and host defense in 
humans and mice [103]. In the case of H. pylori infection, Th17 cells and their associated 
cytokine IL-17A, are increased in H. pylori-infected individuals and in mouse models (discussed 
below) [88, 98, 133, 173, 194, 199].  
 
IL-17A 
IL-17A belongs to the IL-17 family of cytokines in which IL-17F has similar functions [59]. IL-
17A binds to the IL-17 receptor IL-17RA and IL-17RC in humans, but only to IL-17RA in mice 
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[106]. CD4+ Th17 cells are not the only cell type secreting IL-17A in humans or in mice. IL-17A 
can also be secreted by γδ T cells, CD3+ invariant natural killer T (iNKT) cells, lymphoid-tissue 
inducer (LTi) cells, Group 3 innate lymphoid cells (ILCs), NK cells, neutrophils and 
macrophages [46, 207]. IL-17A is a multi-functional cytokine that targets many different cells 
such as epithelial cells, fibroblasts, endothelial cell and neutrophils and can induce the 
production of e.g. IL-1β, IL-6, CXCL8, granulocyte colony stimulating-factor (G-CSF), 
granulocyte macrophage colony stimulating-factor (GM-CSF), TNFα and anti-microbial peptide 
production [103, 120, 170]. An important function of IL-17A is to attract neutrophils to the site 
of infection. Thus, deficiencies of IL-17 in mice have been shown to be associated with 
neutrophil defects leading to disease susceptibility [102, 121]. For example, mice deficient in IL-
17RA are highly susceptible to extracellular pathogens, including the bacteria Klebsiella 
pneumonia, the yeast Candida albicans, and the parasite Toxoplasma gondii, [89, 94, 230]. In the 
field of H. pylori, IL-17A is elevated in the gastric tissue of H. pylori infected compared to in un-
infected individuals and can induce CXCL8 secretion by epithelial cells in a dose-dependent 
manner [35, 98, 133, 194]. In addition, the increase of IL-17A in H. pylori-infected individuals 
compared to uninfected individuals is also associated with gastritis [35]. Notably, it has been 
shown that reduced IL-17A responses are associated with lower gastritis score in children 
infected with H. pylori and interestingly the IL-17A response and gastritis were higher in adults 
[195]. However, the association of IL-17A with gastritis may be related to its function in 
recruiting neutrophils to the site of infection, as gastritis is often correlated with neutrophil 
numbers in the tissue. Further, the increase in IL-17A is also associated with increased IL-23 in 
H. pylori-infected individuals [35].  
 
IL-1β 
IL-1β is a pro-inflammatory cytokine that is elevated in the stomach of H. pylori infected 
individuals [24]. IL-1β is secreted in large amounts by macrophages and DCs but can also be 
secreted by neutrophils, monocytes, mast cells, T cells, B cells, endothelial cells and epithelial 
cells [55, 200]. As mentioned previously, it has been shown to enhance IL-17A secretion by T 
cells and ILCs in the presence of IL-6 and IL-23 [38, 200, 211-212]. The receptor for IL-1β is 
the IL-1 receptor I (IL-1RI) which is expressed on a wide range of cells including epithelial cells, 
endothelial cells, and innate and adaptive leukocytes [200]. IL-1 signaling is regulated by the IL-
1R antagonist (IL-1Ra) which is constitutively expressed  and  competes with binding to the IL-
1RI and thereby inhibiting the IL-1 signaling [54]. Importantly, a lack of IL-1 signaling in mice, 
results in a defect in the generation of IL-17A-producing T cells [211]. A subset of NLRs which 
is activated during microbial infection is involved in the formation of the inflammasome [30]. 
Furthermore, activation via TLRs will lead to the synthesis of the inactive form of IL-1β, pro-IL-
1β [143]. Notably, in H. pylori infection, activation via Nod1 can in turn lead to activation of the 
transcription factor NF-κB, activation of the inflammasome and caspase-1 that can cleave pro-
IL-1β to biologically active IL-1β which then can be secreted [143, 189].  
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IL-23 
IL-23 consists of the p40 subunit, paired with a distinct second chain p19 subunit [167]. IL-23 is 
secreted mainly by macrophages and DCs [9]. IL-23 binds to the IL-23 receptor (IL-23R) which 
is expressed by macrophages, DCs, T cells, NK cells, δ T cells, iNKT cells and ILCs [46, 111]. 
As discussed earlier, secretion of both IL-1 and IL-23 has been suggested to promote IL-17A 
responses in chronic inflammatory disorders [7, 38-39, 45, 211]. However, IL-23 was later 
shown to be necessary for the maintenance of the Th17 cells and not in the induction phase. In H. 
pylori infection, IL-23 has been proposed to be an important cytokine in promoting chronic 
gastritis in humans as it can be found in higher levels in H. pylori-infected gastric mucosa [35, 
96]. In addition, in mice it has been shown that H. pylori-infected IL-23p19-/- mice have reduced 
inflammation compared to infected wild-type mice which may be related to the effect of IL-23 
on IL-17A levels and consequently reduced neutrophil recruitment into the tissue [88].  
 
B cell responses 
H. pylori also induces local and systemic humoral immune responses with antibody production. 
B cells expressing CXCR5 can be recruited to the site of infection by chemokines such as 
CCL28 and CXCL13 and subsequently form germinal centers [116, 155]. Symptomatic and 
asymptomatic H. pylori-infected individuals have elevated H. pylori-specific secretory IgA 
antibodies [144]. In addition, H. pylori-infected individuals have increased levels of serum IgG 
and IgA, which can be used as a marker for diagnosis of the infection [132, 145]. In a birth 
cohort study in Bangladesh it was shown that passive transfer of H. pylori-specific IgA via breast 
milk to infants, from mothers with high antibody titers, resulted in later acquisition of infection 
than those in infants receiving breast milk with low antibody titers [26]. In addition, it has been 
shown that H. pylori antigen-specific IgA locally in the stomach and IgG in serum are elevated 
in infected compared to naïve mice [62, 215]. 
 
Gastritis  
Inflammation in the stomach tissue (gastritis) is characterized by a massive infiltration of cells 
which often occurs in response to the cytokines and chemokines induced during H. pylori 
infection. Interestingly, H. pylori infection causes gastritis in all infected individuals, but not all 
individuals develop clinical symptoms. In symptomatic individuals, evaluating the severity of 
gastritis is an important aspect that can be related to the symptoms, making scoring and 
classifying highly important. The gastritis can be classified and graded based on The Sydney 
System which is a standardized system in which cell infiltration, tissue changes and overall 
damage can be assessed [58]. The pattern of gastritis in the stomach has been associated with 
increased risk of developing gastric cancer or peptic ulcer disease depending on the location in 
the stomach at which the gastritis is most prominent - corpus or antrum, respectively [108]. 
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Furthermore, chronic infection may also induce gastric atrophy (loss of normal mucosa and 
destruction of parietal and chief cells in the corpus), intestinal metaplasia (the formation of 
intestine-like epithelium) and dysplasia (changes in epithelial cells) which are all risk factors for 
developing gastric cancer [108]. The association of inflammation with multiple pro-
inflammatory cytokines is evident from studies in both humans and animal models [111, 200].  
 
Despite a strong pro-inflammatory response induced in the stomach of H. pylori-infected 
individuals, the infection is chronic and is rarely spontaneously eradicated. One explanation 
could be the presence of Tregs that dampen excessive inflammation at the cost of persistent 
colonization of the bacteria [128, 188]. Clearly, this is a problem, as some H. pylori-infected 
individuals can remain asymptomatic but still develop gastric malignancies due to the chronic 
inflammation (if they are colonized with bacteria with certain virulence factors and have a 
genetic predisposition). Treatment of the infection using antibiotics may be effective in 
individual cases, but as many individuals are asymptomatic they would not seek treatment. In 
symptomatic H. pylori-infected individuals and those individuals carrying risks for gastric 
malignancies, a vaccine as mentioned previously would protect against infection and minimize 
the likelihood of re-infection, thus also minimizing medical and clinical health problems 
associated with symptomatic infection.   
 
Helicobacter pylori mouse model 
To be able to study the immune responses after vaccination, mouse models of H. pylori have 
been utilized and the most well established and widely used model is the H. pylori Sydney strain 
1 (SS1) infection in C57BL/6 mice. H. pylori SS1 was originally isolated from a patient with 
peptic ulcer disease and was mouse adapted [115]. The mouse model allows studies of host 
interactions, pathology and more specifically the evaluation of vaccine candidates and 
vaccination strategies. H. pylori SS1 bacteria colonize at high levels in the mouse stomach 
starting two weeks post-infection and stable for up to eight weeks after infection [181].   
 
Mucosal vaccination against Helicobacter pylori infection 
In mouse models it has been shown that vaccination can boost the infection-induced immune 
responses leading to reduction in bacterial load in the stomach and importantly can protect 
against reinfection [74, 183]. In addition to specific H. pylori antigens, an effective adjuvant is 
required to induce protection against H. pylori infection after mucosal immunization [68, 216]. 
Key features of a successful vaccination are the choice of antigens, adjuvant and route of 
vaccination. These combinations have been evaluated in animal models such as mice, with 
immunizations both prophylactically (before infection) and therapeutically (after infection).  
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Antigens 
H. pylori bacteria have been shown to induce a strong and robust immune response in both 
humans and mouse models. Several strategies can be identified regarding the choice of the 
antigen used for the immunizations e.g. (i) whole cell formalin-inactivated bacteria (ii) vectors 
expressing H. pylori antigens e.g. Salmonella-expressing urease (iii) immunodominant antigens, 
e.g., CagA and urease (iv) boost responses to weakly immunogenic antigens for example, HpaA, 
BabA and SabA. In mouse models, several antigen preparations have been used and shown to 
induce protection against H. pylori infection. Whole cell vaccineshave been widely used and 
induce protection after vaccination in mice and enhanced immune responses in infected human 
volunteers [104, 181]. Recombinant antigens such as urease B (large subunit) (UreB), CagA, 
VacA, HpaA and NAP have been evaluated, either alone or in different combinations and they 
have been found to be protective in mice [69, 74, 99, 142, 191, 214]. In addition, combinations 
of purified recombinant antigens of the urease (UreA/UreB) have been used in human volunteers 
and induce H. pylori-specific responses [23]. Clinical trials performed with a candidate H. pylori 
vaccine containing a Salmonella enteric serovar vector expressing H. pylori urease A and B and 
subsequently challenged with H. pylori [6] showed lack of protection against H. pylori infection. 
However, it was evident that enhanced CD4+ T cell responses correlated with lower bacterial 
load irrespective of immunization status and that the vaccination did not exacerbate the H. pylori 
infection-induced gastritis. In mice, intranasal (IN) or sublingual (SL) immunization with 
recombinant HpaA or UreB alone induced immune responses, although weak. However, when 
both antigens were combined, together with cholera toxin (CT), strong immune responses were 
generated and induced protection against H. pylori infection [69, 164].  
 
Adjuvants 
In vaccines, adjuvants are used to enhance the immune response towards a specific antigen. 
Mucosal adjuvants have the ability to enhance antigen presentation by APCs and thus T cell 
activation occurs more efficiently [2]. In mice, the standard mucosal adjuvant used most often is 
CT from Vibrio cholerae. It induces strong humoral and cellular immune responses to co-
administered antigen [182-183, 214]. Studies in the H. pylori mouse model have shown that an 
adjuvant such as CT is essential for protection against H. pylori infection after mucosal 
immunization [18]. CT can promote strong T cell responses and more specifically T helper (Th1) 
and T helper (Th17) responses to the co-administered antigen through activation of APCs [18, 
52, 68, 217]. Only a few adjuvants are licensed for use in humans thus far, and a strong and safe 
mucosal adjuvant is still lacking. Clinical trials have used native or attenuated enterotoxins from 
enterotoxigenic Escherichia coli (ETEC) in humans, but thus far the majority have still shown 
safety and toxicity problems. A major focus in mucosal adjuvant research has been the 
generation of non-toxic derivatives of CT or the heat labile toxin (LT) from ETEC while still 
retaining significant adjuvanticity [174].  
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CT and LT toxins belong to the AB toxin group which is typically characterized by an 
enzymatically active A subunit and a binding B subunit. The A subunit consists of the 
components A1 (CTA1/LTA1), which is the enzymatically active ADP-ribosyltransferase, and 
A2 (CTA2/LTA2) which links the A subunit to the B subunit (CTB/LTB). CT binds via CTB to 
the membrane bound ganglioside, GM1, present on most nucleated cells, while LT binds through 
LTB to not only GM1 but also other receptors present in the intestine. When CTB or LTB has 
bound to its receptor, the molecule including the A subunits is internalized by endocytosis into 
the host cells and transported to the endoplasmic reticulum (ER). The A and B subunit 
subsequently dissociate and the A1 subunit is translocated to the cytoplasm by an unknown 
pathway. Once in the cytosol, the A1 subunit ADP-ribosylates Gs proteins, resulting in activation 
of adenylate cyclase, and increased intracellular levels of cAMP (toxicity). The increased cAMP 
will cause electrolyte imbalance in the host cell and ultimately cause water secretion and diarrhea 
[190]. Mutations introduced in the enzymatically active A1 subunit can detoxify these molecules 
while still retaining their adjuvant function.  
 
CTA1-DD is an attenuated form of CT consisting of an A1 subunit genetically fused to the dimer 
of the Ig-binding D region (DD) of Staphylococcus aureus protein A (SpA). The DD moiety in 
CTA1-DD targets all B cells [8, 162]. In mice, IN immunization with H. pylori lysate antigens 
and CTA1-DD does induce protection against H. pylori infection although not as efficiently as 
when CT is used as an adjuvant [13]. Both native LT and attenuated versions of LT e.g. LTK63 
have been used in mice and humans and confers protection against H. pylori infection although 
native LT predictably, caused side effects in humans [23, 74, 142]. Another version of attenuated 
LT is the LT (R192G) which has a single amino acid substitution, resulting in reduced 
enterotoxicity compared to native LT. In humans, LT (R192G) alone induced antibody responses 
in the stomach of H. pylori-negative individuals [125], and was found to be safe and well 
tolerated [104]. However, when included in an H. pylori vaccine, a subset of the volunteers 
experienced mild diarrhea [104]. To overcome this, a second mutation was introduced in the LT 
molecule at site 211 which resulted in the double mutant LT (dmLT) (R192G/L211A). The 
second mutation dramatically decreased cAMP production compared to native LT in vitro in 
epithelial cell lines and in vivo as measured by fluid secretion in the intestine in a patent mouse 
assay [160]. In mice, dmLT has been shown to induce strong antibody and Th17 responses [113, 
161].  
 
The question still remains: How can dmLT, with its minimal ADP-ribosylating activity [160-
161], be as potent as CT in inducing mucosal immune responses? In an attempt to elucidate the 
adjuvant mechanism of dmLT, Norton et al [160] reported that the mutations in the dmLT 
molecule that prevent the proteolytic cleavage of LT-A subunit into A1 and A2 subunits, also led 
to rapid degradation of the A-subunit in the cytosol of intestinal epithelial cells [160]. They also 
showed that a higher dose of dmLT was needed to induce cAMP in Caco-2 cells in vitro, 
compared to native LT [160]. Thus, dmLT not only induced much reduced cAMP formation in 
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cells, but its A-subunit rapidly degraded, thus generating limited enterotoxicity. It is possible that 
the very short half-life of the A subunit of dmLT within the cells allows stimulation of low but 
sufficient amounts of cAMP for adjuvanticity without leading to enterotoxicity as also proposed 
by Norton et al [160]. Further studies to elucidate the effect of dmLT on different cell types and 
the adjuvant function of dmLT and CT in the presence or absence of cAMP inhibitors may help 
to clarify the level of cAMP important for the adjuvant function of dmLT.  
 
Currently, the vaccines against H. pylori infection that have been evaluated in clinical trials have 
either not studied the effect on bacterial load or have reported meager T responses to co-
administered antigen [139]. In addition, an effective non-toxic mucosal adjuvant is of the essence 
as those that have been used in clinical trials together with H. pylori antigens components have 
shown adverse effects in human volunteers [23, 31, 104, 149].   
 
Routes of immunization 
Mucosal vaccination has been extensively investigated due to the large number of pathogens 
invading and causing disease at our mucosal surfaces. In mice, the most commonly investigated 
routes of immunizations are intragastric (IG), IN and SL while rectal and intravaginal routes 
have been evaluated to a less extent. Rectal immunization against H. pylori infection has been 
evaluated in humans and in mice and although this route of immunization confers immune 
responses, other routes of immunization are preferable [99, 206]. In human volunteers, 
intravaginal immunization has been shown to induce local immune responses, but does not 
induce immune responses in the gut [148]. In humans, the IG route has been by far the most 
often used for vaccination against H. pylori infection [23, 104, 125]. In mice, protection against 
H. pylori infection has been demonstrated after prophylactic and therapeutic IG vaccination [142, 
183, 214]. However, as the IG route delivers the antigen and adjuvant directly into the stomach, 
there are concerns that the antigens and adjuvants might be degraded because of the harsh 
environment and thus a large dose may be required to induce protection. The IN route of 
vaccination has been evaluated in mice and confers protection against H. pylori infection [13, 
99]. This route eliminated the problem of components of the vaccine degrading but instead 
introduced new safety issues such as translocation of antigen and adjuvant to the olfactory bulb 
of the brain in addition to lack of efficacy in humans relative to mice [92]. The SL route of 
immunization has been evaluated in mice as an alternative route to the nasal route for inducing 
mucosal immune responses [49]. The SL route has previously been used as a route of sensitizing 
and treating allergic asthma in humans and for vaccination against influenza virus in mice with 
promising results [197]. In mice, immunization via the SL route using the adjuvant CT and 
ovalbumin as antigen increases the number of CD11c+ DCs in the SL mucosa which migrate to 
the cervical lymph node (CLN) to present the antigens and generate antigen-specific T cell 
responses [47, 204]. Immunizing via the SL route also increase antibody responses both 
systemically and mucosally and protects against a lethal dose of influenza virus [47, 205]. The 
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SL route of immunization also induces a strong H. pylori antigen specific responses and 
protection against H. pylori infection in mice [69, 182]. The SL route of immunization can also 
induce immune responses in a wide range of mucosal tissues (e.g. genital tract, respiratory 
system, small intestine and stomach) in mice, and is a preferable route for immunization in 
humans [49, 110, 159]. In addition, the antigen or adjuvant when delivered via the SL route does 
not translocate to the olfactory bulb [198], minimizing safety concerns.  
 
Immune responses after mucosal vaccination in mice 
Vaccine-induced protection is associated with increased levels of antibodies. However, studies 
using gene knockout mice have shown that mice deficient in mature B cells and antibody 
responses are still protected after IG vaccination and thus the humoral response does not seem to 
be essential for vaccine-induced protection [62]. Studies have shown that CD4+ T cells and not 
CD8+ T cells are essential for vaccine-induced protection against H. pylori infection [62, 168]. 
More specifically the Th1 and Th17 responses, with subsequent IFNγ and IL-17A production 
strongly correlate with vaccine-induced protection [52, 68, 182, 221]. The robust immune 
response induced after vaccination and challenge with H. pylori, manifests itself as inflammation 
in the stomach referred to as “post-immunization gastritis” [72, 77, 183]. Post-immunization 
gastritis has been shown to be transient and resolves when the bacteria are eradicated from the 
stomach of vaccinated mice [72]. The gastritis is accompanied by a major influx of 
hematopoietic cells and secretion of cytokines and chemokines. It has been shown that there is a 
strong influx of neutrophils and increase in the chemokines and receptors for neutrophil influx, 
CXCL2, CXCL5 and CXCR2 within 7 days after vaccination and infection with H. pylori [14, 
67]. Subsequently, vaccine-induced protection against H. pylori infection has been shown to be 
neutrophil dependent [52]. In addition, mast cells have been shown to be important for vaccine-
induced protection in a H. felis model in which mice had increased levels of bacteria in their 
stomach when mast cells were depleted [220]. Furthermore, mast cell-deficient mice have been 
shown to be partially protected against H. pylori infection after vaccination, but, with lower 
numbers of neutrophils in the stomach [57]. Vaccination and infection with H. pylori also 
induced the expression in the mouse stomach of CXCL10 (attracts Th1 cells), CCL20 (attracts 
Th17/DCs) and CCL8 (attracts eosinophils) and their receptors [67]. Furthermore, it has also 
been shown that there is an increased frequency of Th1 cells, eosinophils and DCs in the 
stomach which correlated with protection against H. pylori infection [67].  
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Aims 
In a Helicobacter pylori mouse model;  
 
 To evaluate immune responses after sublingual vaccination with a candidate H. pylori 
vaccine containing H. pylori antigens and a de-toxified double mutant heat labile toxin 
(dmLT) from enterotoxic Escherichia coli as a mucosal adjuvant.  
 
 To assess the role of IL-17A and IFNγ in protection against H. pylori infection and 
inflammation after sublingual and intragastric vaccination.  
 
 To investigate the role of IL-1 signaling and IL-23 in inducing IL-17A responses after 
sublingual vaccination 
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Key Methodologies 
Mice  
For all experiments, wild-type (WT) specific-pathogen-free C57BL/6 mice were purchased from 
Taconic, Denmark or Harlan Laboratories, Horst, Netherlands. Interferon-γ knockout (IFNγ-/-) 
mice from Genentech were bred at the Laboratory for Experimental Biomedicine and used in 
paper II. Interleukin-1 receptor I knock-out (IL-1RI-/-) mice were obtained from the Jackson 
Laboratory, ME and bred at the Laboratory for Experimental Biomedicine and Interleukin-23 
p19 subunit knock-out (IL-23p19-/-) mice were provided by Dr. Rene de Waal Malefyt, Merck 
Research Laboratories, CA, were used in paper III. All gene-knockout mice were obtained on a 
C57BL/6 background. In Appendix I, ovalbumin T cell transgenic mice (OT-II) were used which 
are homozygous for a transgene that encodes a T-cell receptor specific for chicken ovalbumin 
(amino acids 323-339), presented on the MHC class II molecule I-Ab (from in house breeding). 
All mice were housed in microisolators at the Laboratory for Experimental Biomedicine, 
Göteborg University for the duration of the study with food and water provided ad libitum. All 
experiments were approved by the Ethical Committee for Laboratory Animals in Gothenburg, 
Sweden. 
 
Human volunteers 
Appendix II 
Antrum and corpus stomach tissue biopsies were taken from Swedish volunteers as previously 
described [5]. Written consent was obtained from each volunteer before participation and the 
study approved by the Human Research Ethics Committee in Gothenburg as described in [5]. 
Briefly, blood was collected from all volunteers and screened using a whole blood quick test to 
detect H. pylori positivity (Quick Vue H. pylori gII test; Quidel, San Diego, CA, USA) and the  
infection was also confirmed by  culture from biopsies on H. pylori selective plates and ELISA 
to detect H. pylori specific serum antibody responses. Biopsies were also taken and used for 
histopathological scoring and immunohistochemistry. Three different groups of volunteers were 
analysed (i) H. pylori-negative (Hp-) individuals; (ii) Asymptomatic H. pylori-positive (Hp+) 
individuals without corpus atrophy or intestinal metaplasia and; (iii) H. pylori-positive with 
corpus atrophy (Hp+ CA)  and none or mild intestinal metaplasia. Biopsies were frozen and kept 
at -70 ˚C until use for immunohistochemistry.  
  
Cultivation of H. pylori SS1 for infection  
The H. pylori SS1 was used for infecting the mice [115]. The bacteria were cultured on agar 
plates and subsequently transferred to a broth and cultured additionally overnight [182]. The 
bacteria were visualized under a microscope to check for motility before infection of mice. 
Before IG infection of mice, the optical density (OD) was adjusted to 1.5, and a single dose of 
approximately 3x108 viable bacteria was given intragastrically to each mouse [183].  
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H. pylori lysate antigens and recombinant antigen preparation for immunizations and 
ELISA  
For immunizations, H. pylori lysate antigens from the strain Hel 305 (CagA+, VacA+) isolated 
from a duodenal ulcer patient was prepared as previously described [123, 181-182]. The bacteria 
were grown to confluence on agar plates and the bacterial harvest was suspended phosphate-
buffered saline (PBS) and sonicated on ice. After centrifugation to remove the bacterial cell 
membranes the supernatant was sterile filtered to remove any possible contamination with whole 
bacteria. For SL immunizations, thawed aliquots of the H. pylori lysate antigens were 
immediately freeze-dried and reconstituted to a protein concentration of 20 mg/ml (Paper II-III) 
or 40 mg/ml (paper I) to reduce the volume used for the immunization to a maximum of 10 l 
(including the adjuvant). For IG immunizations the same concentration of the antigens was used 
as for SL immunizations. The coating antigen for enzyme-linked immunosorbent assay (ELISA) 
to detect H. pylori specific antibodies, H. pylori membrane protein (MP) antigen, from strain Hel 
305 (MP Hel 305) was prepared as described in detail in paper I. The antigen preparations were 
aliquoted and stored at -70°C until further use and not subjected to multiple freeze-thaw cycles. 
Purified recombinant H. pylori antigens HpaA (rHpaA) and UreB (rUreB) used for 
immunizations were prepared as described previously [69] and (Paper I).  
 
Reconstitution of adjuvants for immunization  
Lyophilized CT from Vibrio cholerae (Sigma Aldrich) and dmLT (R192G/L211A) from E. coli 
were prepared as described [160] and reconstituted to a concentration of 1 mg/ml and stored at -
70˚C and 4˚C respectively until further use. 
 
In vivo neutralizing antibodies  
For in vivo neutralization of IL-17A in paper II, a rat anti-IL-17A IgG monoclonal antibody 
clone JL7.1D10 (Merck Research Labs, Palo Alto, CA) was used [37]. Purified rat IgG antibody 
(Sigma Aldrich) was used an isotype control. A concentration of 300 µg /mouse and occasion of 
neutralizing antibodies or isotype control antibodies was administered intraperitoneally (i.p.) in a 
volume of 300 µl.  
 
Experimental setup  
Prophylactic SL immunization was carried out by carefully placing a total volume of 10 µl of H. 
pylori lysate antigens reconstituted in CT, dmLT or PBS without bicarbonate buffer through a 
micropipette under the tongue of the mice. Prophylactic IG immunization was performed using a 
feeding needle, placing a total volume of 300 µl of H. pylori lysate antigens and CT or dmLT in 
3% sodium bicarbonate buffer directly into the stomach.  
Both immunizations were administered under deep anesthesia (Isoflurane; Abbott Scandinavia 
AB, Solna, Sweden).  
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Figure 1. Experimental setup of the in vivo experiments included in the thesis. 
 
Paper I  
Each mouse was prophylactically immunized according to one of the following protocols.  
1) SL immunization at biweekly intervals with 400 μg H. pylori lysate antigens and 10 µg CT or 
10 µg dmLT.  
2) IG immunization at biweekly intervals with 400 μg H. pylori lysate antigens and 10 μg CT or 
10 µg dmLT.  
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3) SL immunization at biweekly intervals with 400 μg of H. pylori lysate antigens alone or 20 µg 
dmLT alone (antigen and adjuvant controls).  
4) SL immunization at biweekly intervals with 50 µg rHpaA+50 µg rUreB and 10 µg of CT or 
20 µg dmLT  
 
Two weeks after the last immunization the mice were challenged with live H. pylori SS1 bacteria 
Animals were sacrificed at two-three weeks after challenge, and the number of H. pylori bacteria 
in the stomach of individual mice was determined (Fig. 1).  
 
Paper II and III 
Before starting these next set of experiments described below, the amount of H. pylori lysate 
antigens needed for SL and IG immunization was titrated. The results showed that 200 µg H. 
pylori lysate antigens and CT induced the similar immune responses and protection against H. 
pylori infection as 400 µg and thus we continued our experiments using 200 µg H. pylori lysate 
antigens for the immunizations (data not shown).  
1) SL immunization at biweekly intervals with 200 μg H. pylori lysate antigens and 10 µg CT 
(Paper II and III).  
2) IG immunization at biweekly intervals with 200 μg H. pylori lysate antigens and 10 μg CT 
(Paper II).  
 
Two weeks after the last immunization, mice were challenged with live H. pylori SS1 bacteria 
and sacrificed 2, 3 or 5  weeks after challenge and the number of bacteria in the stomach was 
determined by quantitative culture (Paper II and III). In Paper II sublingually immunized and 
unimmunized IFNγ-/- mice were injected i.p. with 300 µg/mouse neutralizing anti-IL-17A or 
isotype IgG antibody on day 5, 8 and 11 after challenge. At day 14 after challenge the mice were 
sacrificed and bacterial counts in the stomach assessed along with cellular immune responses, 
antibody production and cytokine responses.  
 
Appendix I 
Mice were immunized via the SL or IG route and challenged as described in (1) and (2) for Paper 
I. Stomach tissue was assessed for IL-17A positive cells by immunohistochemistry.  
 
To block the egress of lymphocytes from the lymph nodes, the drug FTY720 (Cayman 
Chemicals, Ann Arbor, MI), a structural analog of sphingosine and potent agonist of the 
sphingosine-1-phosphate receptors was used. FTY720 was diluted to 0.5 mg/ml in physiological 
saline and each mouse was administered 0.025 mg i.p. every 48 h for maximum 6 days. Mice 
were immunized via the SL or IG route on day 1 (after FTY720 injection) and sacrificed on day 
8. To ensure that the FTY720 treatment was efficient and that no T cells exited the lymph nodes, 
blood was collected on day 6 and day 8 stained for lymphocytes CD3, CD4 and CD8 and 
analyzed by Flow cytometry.   
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Expansion of CD11c+ dendritic cells in vivo  
Appendix I 
Flt3L secreting B16-F10 melanoma was obtained from Nicolas Mach [135] and was stored in 
liquid nitrogen, thawed and cultured for 2-3 days in a 25 mm2 flask in Iscove´s basal medium 
(Biochrome, Berlin, Germany) supplemented with fetal calf serum, 2-mercaptoethanol , 1mM L-
glutamine and gentamycin (Iscove’s complete medium) at 37°C and in 5% CO2 atmosphere. On 
the day of injection, the cells were collected, washed and resuspended in fresh Iscove´s complete 
medium and counted. Each mouse was administered a total of 1 x 106 cells injected 
subcutaneously. The tumor cells upon injection into mice forms a solid tumor which secrete 
Flt3L that has the ability to expand CD11c+ dendritic cells in lymph nodes and spleen. The mice 
were palpated daily to follow tumor growth and sacrificed when the tumor size had reached no 
more than 10 mm in diameter. 
 
Quantitative culture of H. pylori SS1 from the stomach  
Papers I-III 
To evaluate bacterial colonization in the stomachs of the mice, one half of each stomach was 
homogenized in brucella broth using a tissue homogenizer (Ultra Turrax, IKA Laboratory 
Technologies, Staufen, Germany). Serial dilutions of the homogenates were plated on blood 
skirrow agar plates (BD Biosciences). After 7 days of incubation at 37°C under microaerophilic 
conditions, visible colonies with typical H. pylori morphology were counted, and a urease test 
was performed for any uncertain colonies. Calculations of the number of bacteria per stomach 
were done as previously reported [163].  
 
Determination of cytokines IL-17A and IFNγ in stomach tissue extracts  
Papers II-III 
IL-17A and IFNγ in the stomach was determined in tissue extracts prepared using a 2% saponin-
PBS solution as previously described [163]. IL-17A in the extracted stomach tissue supernatant 
were analyzed using the mouse cytometric bead array (CBA) flex set kit (BD Biosciences) 
according to manufacturer’s instructions. To ensure that cytokines could be detected correctly, an 
experiment was performed where saponin tissue extracts were spiked with different 
concentrations of the recombinant cytokine and analyzed. This experiment showed that the CBA 
flex set kit was able to specifically detect and bind to cytokines in saponin tissue extracts. 
Furthermore, two different kits; CBA Th1/Th2/Th17 kit and CBA flex set kit were used during 
the study to detect cytokines in saponin tissue extracts and supernatants from proliferation assays 
and comparison of the two kits showed that they gave similar results.  
 
 
Determination of gene expression in stomach tissue 
Papers I, III 
RNA isolation and cDNA preparation 
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The stomach was excised and dissected along the greater curvature. Any loose stomach contents 
were removed by washing in PBS. One longitudinal strip including the corpus and antrum were 
cut and placed directly into RNAlater and stored at -70°C. For RNA isolation, the tissue was 
thawed and transferred to RLT lysis buffer and homogenized using a Tissue Lyser II. Total RNA 
was extracted using RNeasy mini kit (Qiagen) and thenstored at -70°C. RNA purity and 
concentration was measured using the fluorospectrometer Nanodrop ND-1000. RNA (2 µg) was 
reverse transcribed into cDNA using the Omniscript kit.  
 
Real Time PCR 
All real-time PCRs (RT-PCRs) were run in 96-well plates using the standard amplification 
conditions described for the 7500 RT-PCR system and 40 ng cDNA, 10 µl 2× Power SYBR 
green master mix (Applied Biosystems, Foster City, CA), and 1 µl of gene-specific 
oligonucleotide primers (Eurofins MWG Operon, Ebersberg, Germany). The reactions were run 
in duplicate, and β-actin was used as the reference gene in all experiments. The difference 
between β-actin and the target gene (∆CT) was determined, and the relative expression was 
calculated using the formula 2∆CT. The values were adjusted so that the mean in the infection 
control group was set to 1. The negative control (lacking reverse transcriptase) giving the lowest 
CT value was used to determine the detection limit. The sequences used in paper I, II and III are 
shown in Table 1 and have been previously published [201].   
 
Table 1. Oligonucleotide primers used for quantitative PCR 
 Primer sequence 
Gene Forward Reverse 
β-actin 5´-CTGACAGGATGCAGAAGGAGATTACT-3´ 5´-GCCACCGATCCACACAGAGT-3´ 
CD4 5´-ACTGGTTCGGCATGACACTCT-3´ 5´-TCCGCTGACTCTCCCTCACT-3´ 
IL-17 5´-CCCTTGGCGCAAAAGTG-3´ 5´-TCTTCATTGCGGTGGAGAGT-3´ 
IFNγ 5´-GCATAGATGTGGAAGAAAAGAGTCTCT-3´ 5´-GGCTCTGCAGGATTTTCATGT-3´ 
 
Grading inflammation in stomach tissue  
Papers I, II, III 
A longitudinal strip from the entire longer curvature of the stomach was taken and fixed in 4% 
phosphate-buffered formalin and then embedded in paraffin. Sections, 8 µm thick were cut and 
stained with hematoxylin and eosin. The slides were then examined by light microscopy (x100), 
and the extent of gastritis was graded based on the Sydney system of scoring gastritis as 
described previously [180]. Briefly, sections were graded and given a score for parietal cell 
destruction (1-6), chief cell destruction (1-6) and cell infiltration (1-4) giving a maximum score 
of 16. Grading was done as follows: Grade 0–1, normal gastric mucosa that contained few 
lymphocytes scattered throughout the submucosa; Grade 2, small aggregates containing three to 
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four layers of cells in the mucosa or sparse infiltrates of cells in the submucosa covering ~5% of 
the section; Grade 3, frequent and larger infiltrates extending into the mucosa; Grade 4, 
infiltrates spanning half to the entire width of the mucosa; Grade 5, partial or complete (grade 6) 
obliteration of parietal and chief cells with hyperplasia of mucous and epithelial cells. 
 
Immunohistochemistry staining for IL-17A in mouse stomach tissue 
Appendix I 
A vertical strip from the entire stomach was taken and frozen in embedding medium OCT 
(Histolab, Göteborg, Sweden) in ice-cold isopentane cooled by liquid nitrogen and the frozen 
blocks were stored at -70°C until further use. Sections (7 µm) were cut and allowed to dry 
followed by fixation with 100% ice-cold acetone for 10 minutes at 4 ˚C. Sections were 
permeabilized with 0.5 % Triton X-100 (Sigma Aldrich) for 10 min and then blocked with 10 % 
goat serum (Sigma Aldrich) and Fc-γ receptor block for 45 minutes. The blocking solution was 
blotted out and primary antibody rat anti mouse IL-17A-FITC (eBioscience) or rat isotype-FITC 
control (eBioscience) was added in 0.1 % Triton X-100 and incubated for 60 minutes. Sections 
were washed in PBS and mounted using mounting medium prolong® gold antifade (Life 
Technologies, Carlsbad, CA) containing DAPI (nuclear stain). The IL-17A staining was then 
visualized using a fluorescence microscope (Zeiss Axioplex 2) and pictures of the positive 
staining in the entire stomach tissue were taken. The pictures were analyzed using the Biopix 
software (Biopix, Göteborg, Sweden) for quantification of IL-17A+ cells. 
 
Immunohistochemistry staining for IL-17A in human stomach tissue 
Appendix II 
Biopsies from human volunteers were taken from the antrum and corpus of H. pylori negative 
patients (n=6), H. pylori positive patients (n=6) and H. pylori positive patients with corpus 
atrophy (n=5). The biopsy of the stomach was taken and frozen in embedding medium OCT 
(Histolab) in ice-cold isopentane cooled by liquid nitrogen and the frozen blocks were stored at -
70°C until further use. Sections (7 µm) were cut and allowed to dry followed by fixation with 
100% ice-cold acetone for 10 minutes at 4 ˚C. Sections were permeabilized with 0.5 % Triton X-
100 (Sigma Aldrich) for 10 min and then blocked with 10 % human AB serum 2 % naïve mouse 
serum and 10 % bovine serum albumin (Sigma Aldrich) for 60 minutes. The blocking solution 
was blotted out and primary antibody mouse anti human IL-17A-FITC (eBioscience) or mouse 
isotype-FITC control (eBioscience) was added in 0.1 % Triton X-100 and incubated for 60 
minutes. Sections were washed in PBS and mounted using mounting medium prolong® gold 
antifade (Life Technologies) containing DAPI. The IL-17A staining was then visualized using a 
fluorescence microscope (Zeiss Axioplex 2) and pictures of the positive staining in the entire 
stomach tissue were taken. The pictures were analyzed using the Biopix software (Biopix) for 
histological quantification of IL-17A+ cells. 
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Antibody responses 
Papers I-III 
H. pylori-specific IgA antibodies in the stomach against MP Hel 305 were determined in the 
stomach tissue extracts by ELISA as described in detail in Paper I.  
Serum antibody titers were also determined by ELISA against MP Hel 305. For IgA the end 
point values that was used was the optical density measured at 490 nm. And for serum IgG 
measurements, the antibody titers are defined as the reciprocal serum dilution giving an 
absorbance of 0.4 above the background.  
 
Determination of H. pylori specific cellular immune responses and subsequent cytokine 
responses in culture supernatant 
Papers  I-III 
For the proliferation assays, single cell lymphocyte suspensions were prepared from the spleen, 
mesenteric lymph nodes (MLN) and cervical lymph nodes (CLN). Cells were seeded (2 x 105 
cells per well) in the presence or absence of boiled H. pylori Hel 305 lysate antigens (4 µg/ml) 
and cultured for 72 hours in Iscove’s complete medium. Supernatants were collected and stored 
at -70°C for subsequent cytokine analysis. To determine proliferation (radioactive thymidine 
incorporation assay), the cells were pulsed with 1 µCi of [3H] thymidine (Amersham Bioscience, 
Buckinghamshire, United Kingdom) for the last 6 to 8 hours of culture. The cellular DNA was 
collected with a cell harvester (Skatron) on glass fiber filters (Wallac) and assayed for 3H 
incorporation using a liquid scintillation counter (Beckman, LKB, Bromma, Sweden). Cytokines 
in culture supernatants was measured using the mouse cytometric bead array kit (BD 
Biosciences) and analyzed according to the manufacturer’s instructions. Supernatant from the 
proliferation assay was analyzed for cytokines IL-17A, IFNγ and TNFα using Mouse 
Th1/Th2/Th17 Cytometric Bead Array kit or Cytometric Bead Assay Flex Set beads according to 
manufacturer’s protocol (BD Biosciences). 
 
Determination of ovalbumin specific cellular responses 
Appendix I 
Preparation and stimulation of DCs 
Single cell suspensions were prepared from the MLN and CLN of Flt3L treated wild-type mice. 
CD11c+ cells were enriched from total MLN and CLN cells by CD11c+ positive selection using 
magnetically labeled MACS beads (Miltenyi Biotech, Bergisch Gladbach, Germany). The purity 
of the CD11c+ DCs in repeated isolations was typically >90%. Enriched CD11c+ dendritic cells 
from MLN or CLN were incubated alone or in the presence of 2 mg/ml Ovalbumin grade VII 
(Sigma Aldrich) together with or without 10-3 µg/ml of CT or dmLT and cultured for 4 hours in 
Iscove’s complete medium. After incubation the cells were washed thoroughly 3-4 times to 
completely remove any residual antigen or adjuvant.  
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Preparation of OT-II T CD4+ T cells and co-culture with stimulated DCs  
Spleen CD4+ T cells ovalbumin transgenic (OT-II) mice were prepared using CD4 positive 
selection kit (Miltenyi Biotech). CD4+ cells in repeated isolations was typically >90%. DCs 
(stimulated or unstimulated) were seeded (1 x 104 DCs per well) together with CD4+ OT-II 
spleen T cells (1 x 105 per well) in a sterile 96-well plate and incubated for 5 days in 37°C in a 
5% CO2 atmosphere. Proliferation of the cells was determined by the radioactive thymidine 
incorporation assay. 
 
Determination of H. pylori specific CD4+ T cell responses 
Appendix I 
Preparation and stimulation of DCs 
Enriched CD11c+ dendritic cells from MLN or CLN were incubated alone or in the presence of 
H. pylori Hel 305 lysate antigens (20 µg/ml), together with or without 10-3 µg/ml of CT or dmLT 
and cultured for 4 hours in Iscove’s complete  medium. The purity of the CD11c+ DCs was 
typically >90%. After incubation, cells were washed thoroughly in order to completely remove 
any residual antigens or adjuvant.  
 
Preparation of CD4+ T cells and co-culture with stimulated DCs 
The MLN was isolated from mice sublingually immunized with H. pylori lysate antigens and CT 
and challenged with H. pylori bacteria. The CD4+ T cells from the MLN were enriched by CD4+ 
positive selection using magnetically labeled MACS beads (Miltenyi Biotech). DCs (stimulated 
or unstimulated) were seeded (1 x 104 DCs per well) together with CD4+ T cells isolated from 
the MLN (1 x 105 + thymidine incorporation assay.  
 
Gene expression in isolated CD11c+ dendritic cells exposed to adjuvant CT or dmLT  
Dendritic cell culture 
CD11c+ cells were enriched from total spleen cells of Flt3L treated C57BL/6 wild-type mice by 
CD11c+ positive selection using magnetically labeled MACS beads (Miltenyi Biotech). CD11c+ 
DCs cultured for RNA extraction were seeded (4 x 106 DCs per well) in the presence or absence 
of 1 µg/ml CT or dmLT and cultured for 4 h in Iscove’s complete medium at 37°C in a 5% CO2 
atmosphere. Cells were collected after incubation, thoroughly washed to remove all culture 
medium and additives and resuspended in 350 µl RLT lysis Buffer (Qiagen) for downstream RT-
PCR application. The samples were stored at -70°C. 
 
RNA extraction and cDNA preparation 
For RNA isolation, the cells were thawed and run through a shredder column (Qiagen for 
homogenization. RNA was extracted by using RNeasy mini kit (Qiagen) and purity and 
concentration was measured using the fluorospectrophotometer NanoDrop ND-1000 (Thermo 
Fisher Scientific). RNA (2 µg) was reverse transcribed into cDNA using the Quantitect kit 
(Qiagen).  
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RT-PCR array 
cDNA (2 µg) were run in 96-well array plates (Mouse dendritic and antigen presenting cell 
array, SA Biosciences/Qiagen) according to manufacturer´s instruction using the 7500 RT-PCR 
Applied Biosystems system and 2x Power SYBR green master mix (Applied Biosystems). An 
average of the housekeeping genes β-actin, glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), β-2 microglobulin (β2m), β-glucuronidase (Gusb) and heat shock protein 90 α b1 
(Hsp90αb1) was used as a controls. The difference between the sample gene and the average 
from the housekeeping genes (ΔCT value) was obtained and the relative fold change and 
expression was calculated by 2ΔCT. The values for all samples were compared to non-stimulated 
cells and expressed as fold-change from non-stimulated samples. Validation was carried out with 
RNA (2 µg) that was first reverse transcribed into cDNA using the Quantitect kit (Qiagen). The 
samples were run in 96-well plates using the standard amplification settings for 7500 RT-PCR 
system and 20 ng cDNA (same amount as used for the array), 10 µl 2x Power SYBR green 
master mix (Applied Biosystems) and 1 µl of gene-specific oligonucleotide primers (Eurofins 
MWG Operon) (table 1). Each sample was run in duplicates and β-actin was used as a 
housekeeping gene control for the validation experiment. The difference between the sample 
gene and β-actin (ΔCT value) was obtained and the relative expression was calculated by 2ΔCT. 
The values for all samples were calculated as fold change from non-stimulated cells.  
 
Flow cytometric analysis 
Paper II and Appendix I 
For cytokine staining, MLN and CLN cells were stimulated with 20 ng/ml Phorbol 12-Myristate 
13-Acetate (PMA, Sigma Aldrich) and 1 µg/ml Ionomycin (Sigma Aldrich) in Iscove’s complete 
medium (Iscove´s medium supplemented with 10% heat-inactivated fetal calf serum, 50 µM 2-
mercaptoethanol, 1 mM L-glutamine, and 50 µg/ml gentamicin) for 2 h at 37°C in a 5% CO2 
atmosphere. After 2 h, 10 µg/ml Brefeldin A (BFA, Sigma Aldrich) in Iscove´s complete 
medium was added to the cells and left for additional 2 h at 37°C in a 5% CO2 atmosphere. 
Surface and intracellular staining was carried out using anti-mouse CD3-PerCP, CD4-Alexa 
Fluor 700, IFNγ-APC (all BD Biosciences) and IL-17A-FITC (eBioscience) and Live/Dead 
Fixable Aqua Dead Cell Stain Kit (Life Technologies). Stained cells were acquired using the 
LSR-II Flow Cytometer and the Diva software (BD Biosciences) and analysis were carried out 
using FlowJo software (FlowJo, Ashland, OR, USA). Stimulation with PMA and Ionomycin 
reduced the frequency of CD3+CD4+ T cells by 5% (data not shown).  
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Figure 2. Gating procedure for Flow Cytometry analysis of IL-17A+ and IFNγ+ in MLN and CLN cells. 
 
 
Statistical analysis.  
Papers I-III and Appendix I-II 
Analysis of variance (ANOVA) with Bonferroni´s (Paper I) or Dunette´s (Paper I) posttest or 
student´s t-test with Welch correction (Paper II, III, Appendix I) was used to compare multiple 
groups of mice using GraphPad Prism software (GraphPad Software Inc., San Diego, CA). For 
all tests, a p value of <0.05 was considered to be statistically significant. 
CD3+CD4+ CD3+CD4+ 
CD4 
CD3 
Live Lymphocytes 
CD3+CD4+ 
CD3+CD4-CD3-CD4-
IL-17A 
IFNγ 
  Results 
35 
 
Results and comments  
PAPER I 
 
Evaluation of dmLT as an adjuvant in a vaccine against H. pylori infection 
The use of CT as an adjuvant in a vaccine against H. pylori infection has provided important 
insights into the protective immune mechanisms against H. pylori infection. However, the 
inherent enterotoxicity of CT precludes its use in a vaccine for humans. This is due to the fact 
that as discussed previously, CT and the related LT when translocated into the host cell can ADP 
ribosylate the stimulatory Gs proteins of adenylate cyclase resulting in an increase in cyclic 
AMP. These events lead to electrolyte secretion in the intestinal epithelial cells with massive 
watery diarrhea as a consequence. In the last decade several targeted mutations in the CT or LT 
molecule have been constructed with the aim to remove or attenuate the toxic effects while still 
retaining the adjuvant function. One promising molecule is dmLT. The aim of this study was to 
evaluate the efficacy of the newly developed double mutant LT (dmLT) as a mucosal adjuvant 
and compare it with the well-established but toxic adjuvant CT in inducing immune responses 
and protection against H. pylori infection.  
 
Protection against H. pylori infection after sublingual immunization with H. pylori lysate 
antigens and dmLT as an adjuvant   
SL immunization using H. pylori lysate antigens and dmLT led to a significant reduction in 
bacterial load post-challenge which was similar to the reduction seen using CT as adjuvant (Fig 
3, paper I). To confirm the adjuvant effect of dmLT after SL immunization, mice were 
immunized with either dmLT or H. pylori lysate antigens alone which did not decrease the 
bacterial load in the stomach after challenge (paper I). Thus in agreement with our earlier reports 
[182] that, vaccination with a combination of antigen and adjuvant is required for protection 
against H. pylori infection in mice. In addition, IG immunization with either dmLT or CT as 
adjuvant together with H. pylori lysate antigens also reduced the bacterial load in the stomach of 
mice after challenge with H. pylori compared to unimmunized infected mice, but not to the same 
extent as after SL immunization (paper I). 
 
 
Figure 3. Sublingual immunization using dmLT or CT as adjuvant 
and H. pylori lysate antigens protects against H. pylori infection.  
Mice were immunized via SL route with H. pylori lysate antigens and 
dmLT or CT or left unimmunized (Inf) and subsequently challenged with 
live H. pylori bacteria. Three weeks post-challenge, reduction in bacterial 
load as a measure of protection was evaluated by quantitative culture and 
expressed as mean log10 values of bacteria per stomach. n=7 mice/group, 
representative of two independent experiments. Statistically significant 
difference in bacterial load between groups was assessed by unpaired two-
tailed t-test with Welch correction and denoted by *** (p<0.001).   
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Our studies utilized H. pylori lysate antigens for vaccination. Although, the lysate preparation 
contains protective antigens, it also contains several toll-like receptor agonists and thus may not 
be suitable in a future vaccine for humans. Whole cell bacteria and recombinant antigens are 
more likely to be components of a H. pylori vaccine. Indeed, we have previously shown that SL 
immunization with recombinant H. pylori HpaA and H. pylori urease B subunit (UreB) and CT 
was protective against H. pylori infection [69]. Therefore we wanted to evaluate whether 
vaccination with HpaA and UreB with the non-toxic dmLT adjuvant could reduce the bacterial 
load in the stomach of mice. Our results show that, SL immunization with a combination of 
HpaA and UreB and dmLT significantly reduced the bacterial load in the stomach after challenge 
compared to unimmunized infected mice (paper I).  
 
Stomach cytokine responses and inflammation after sublingual immunization with H. pylori 
lysate antigens and dmLT 
Previous immunization studies using CT as adjuvant have shown that enhanced Th1 and Th17 
response in the stomach was correlated with reduction in bacterial load in the stomach of mice 
[67-68]. Whether similar immune responses to co-administered antigens are induced in the 
stomach by dmLT is not known. Thus, we evaluated the CD4, IL-17A and IFNγ responses after 
SL vaccination. SL immunization using dmLT or CT as adjuvant resulted in a similar increase in 
gene transcripts for CD4, IL-17A and IFNγ compared to unimmunized infected mice (Fig 4A-C, 
paper I).  
 
If dmLT is to be used as an adjuvant in a H. pylori vaccine in humans, it is important to evaluate 
whether protection is associated with enhanced inflammation in the stomach (post-immunization 
gastritis). Stomach tissue from vaccinated and unvaccinated mice was evaluated and given a 
score for cell infiltration (0-4), parietal cell destruction (0-6) and chief cell destruction (0-6).  
The score for each mouse from the different criteria was added to give a cumulative maximum 
score of 16. In sublingually immunized mice, a statistically significant increase in inflammation 
score was seen when using a vaccine containing H. pylori lysate antigens and the dmLT as 
adjuvant compared to that in unimmunized infected mice (Table 2, paper I).  
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Figure 4. Stomach cytokine and CD4 gene expression is upregulated after sublingual immunization against H. 
pylori infection 
Mice were unimmunized or immunized via SL route with H. pylori lysate antigens and dmLT or CT or left 
unimmunized (Inf) and challenged with live H. pylori bacteria. Gene expression of A. CD4, B. IL-17A and C. IFNγ 
was evaluated by RT-PCR in stomach tissue two weeks post-challenge. The difference between β-actin and the 
target gene (∆CT) was determined, and the relative expression was calculated using the formula 2∆CT. The values 
were adjusted so that the mean in the infection control group was set to 1. The bars represent mean, data 
representative of two independent experiments. Statistically significant difference in gene expression between 
groups was assessed by unpaired two-tailed t-test with Welch correction and denoted by * (p<0.05) ** (p<0.01) and 
*** (p<0.001).   
 
Table 2. Inflammation score after sublingual immunization and challenge 
 Inflammation Score  
H. pylori lysate antigens + dmLT 3.4 ± 0.6 *** 
H. pylori lysate antigens + CT 3.2 ± 0.7 **  
Infection control 0.4 ± 0.1 
 
§ Inflammation score in the stomachs of mice sublingually immunized or unimmunized mice post-challenge with 
live H. pylori bacteria. Data represents mean values ± SEM with n= 10 mice /group and pool of two experiments. 
Statistically significant difference between group scoring values for immunized mice compared to unimmunized 
infected mice was assessed by unpaired two-tailed t-test with Welch correction and denoted ** (p < 0.01) and *** (p 
< 0.001).  
 
Our results from paper I show that after SL immunization, the dmLT adjuvant induce strong 
mucosal and systemic immune responses with reduction in bacterial load in the stomach of mice. 
Remarkably, the removal of the toxicity of the molecule did not have a large impact on the 
adjuvant effect of dmLT since the immune responses were similar to those induced by CT.     
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PAPER II  
Comparison of immune responses after sublingual or intragastric vaccination against H. 
pylori infection  
  
Previous studies have shown that both IG and SL immunization routes can enhance immune 
responses and reduce bacterial load in the stomach of mice [182]. We have previously observed 
reduced colonization of the bacteria in the stomach of sublingually compared to intragastrically 
immunized mice [182] (Fig. 5A, Paper I and II). However, to date, protection against H. pylori 
infection and immune responses have not been evaluated and compared directly between the two 
immunization routes (SL and IG) in the same study. Therefore, the aim of the study was to 
understand the underlying immune mechanisms behind the differences in bacterial colonization 
in sublingually and intragastrically immunized mice.  
 
Post-immunization gastritis in the stomach of sublingually or intragastrically immunized mice 
As mentioned previously, post-immunization gastritis was associated with reduction in bacterial 
load and we were therefore interested in comparing the gastritis scores after SL and IG 
immunization in these mice and its relation to the bacterial load. We observed that the 
inflammation score was significantly increased in the stomach of sublingually immunized mice 
compared to unimmunized infected mice (Fig. 5B). The inflammation score in the 
intragastrically immunized mice was also increased compared to unimmunized mice, but the 
difference was not statistically significant (Fig. 5B, paper II). However, there was a statistically 
significant decrease (p<0.01) in the inflammation observed in intragastrically immunized mice 
compared to sublingually immunized mice (Fig. 5B). Thus the lower bacterial load seen in the 
stomach of sublingually immunized compared to intragastrically immunized mice might be 
related to the differences in the induction of local inflammatory response. Indeed, a statistically 
significant inverse correlation was found between the bacterial colonization and inflammation 
score in individual mice (data not shown).  
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Figure 5. H. pylori bacterial load and inflammation score in the stomach of sublingually compared to 
intragastrically immunized mice. Mice were immunized via the SL or IG route with H. pylori lysate antigens and 
CT (SL or IG) or left unimmunized (Inf) and then challenged with live H. pylori bacteria. Two weeks post-challenge 
mice were evaluated for A. Protection by quantitative culture and expressed as mean log10 values of bacteria per 
stomach and B. Inflammation score in formalin fixed stomach tissue stained with hematoxylin and eosin. Data are 
shown as mean values with n=6-10 mice/group and pool of two experiments. Statistically significant difference in 
bacterial load and inflammation score between groups was assessed by unpaired two-tailed t-test with Welch 
correction and denoted by **(p<0.01) and *** (p<0.001).   
 
Cytokine responses in the stomach in sublingually and intragastrically immunized mice  
Next we studied in further detail the immune response in the stomach of sublingually and 
intragastrically immunized mice. As strong Th1 and Th17 responses have been associated with 
reduction in bacterial load in the stomach of immunized mice, we compared the IL-17A and 
IFNγ response in saponin extracts of the stomach tissue after SL and IG immunization. SL and 
IG immunization both induced IL-17A secretion in the stomach to a similar extent compared to 
unimmunized infected mice (Fig. 6A, paper II). There was a tendency for IFNγ secretion to be 
high in some intragastrically immunized mice compared to both sublingually immunized mice 
and unimmunized infected mice (Fig. 6B, paper II). The inflammation score was not related to 
the levels of IL-17A in the stomach as both sublingually and intragstrically immunized mice had 
comparable levels of IL-17A. 
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Figure 6. IL-17A and IFN  secretion in the stomach after sublingual or intragastric immunization, post-
challenge. Mice were immunized via SL or IG route with H. pylori lysate antigens and CT (SL or IG) or left 
unimmunized (Inf) and then challenged with live H. pylori bacteria. Two weeks post-challenge stomach tissue was 
evaluated for A. IL-17A and B. IFNγ levels in saponin extracts showing pg/ 100 mg stomach tissue; n=6-10 
mice/group and mean values depicted on a Log2 scale and pool of two experiments. Statistically significant 
difference in cytokine levels between groups was assessed by unpaired two-tailed t-test with Welch correction and 
denoted by **(p<0.01) and ns (non-significant).   
 
The main source of the IL-17A in MLN after vaccination is CD4+CD3+ T cells   
As we observed increased levels of IL-17A in the stomach of vaccinated mice post-challenge, we 
next analyzed possible cellular source of the IL-17A. MLN cells were isolated from sublingually 
and intragastrically immunized and unimmunized infected mice after challenge. Single cell 
suspensions were stimulated with PMA and ionomycin for four hours and IL-17A and IFNγ 
secretion were evaluated in gated (i) CD3+CD4-, (ii) CD3+CD4+ and (iii) CD3-CD4- cell 
populations. Flow cytometric analysis of MLN cells isolated from sublingually and 
intragastrically immunized mice revealed that the IL-17A was mainly produced by CD3+CD4+ 
cells and to some extent by CD3+CD4- cells (paper II). In addition, CD3-CD4- cells also produced 
IL-17A upon stimulation although not to the same extent as CD3+CD4+ cells (paper II). 
However, IL-17A production from other cell subsets than CD3+CD4+ cells were not increased 
compared to unimmunized infected mice (paper II). When analyzing the IFNγ secretion in the 
same cells, CD3+CD4- cells and not CD3+CD4+ cells were the main source of the cytokine 
(paper II).  
 
In summary, our data suggests that post-immunization gastritis is, inversely correlated with 
bacterial numbers and not IL-17A responses in the stomach of sublingually and intragastrically 
immunized mice 
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PAPERS II and III 
 
Addressing the role of the cytokines IFNγ, IL-1β and IL-23 in vaccine-induced protection 
and post-immunization gastritis 
SL immunization was more efficient in reducing bacterial load in the stomach than IG 
immunization, but it was also associated with increased post-immunization gastritis. As cytokine 
levels of IL-17A and IFNγ was increased after SL immunization, the aim of the study was to 
determine whether protective inflammation can be separated from pathogenic inflammation by 
studying the role of IFN and IL-17A in these two processes. We found that IL-17A was 
important to the antimicrobial response to H. pylori infection in the stomach of sublingually 
immunized mice. Thus, to further validate the role of IL-17A in H. pylori infection we also 
studied the role of IL-17A-associated cytokines IL-1β and IL-23 in vaccine-induced protection 
after SL immunization.  
 
In order to study the function of each cytokine in the H. pylori infection model, we used gene-
knockout mice for IFN, IL-1RI and IL-23p19 and evaluated the protection and immune 
responses in these mice after SL immunization and subsequent challenge with live H. pylori 
bacteria.  
 
Vaccine-induced protection against H. pylori infection after sublingual immunization was 
induced in the absence of IFNγ and IL-23 but was partly dependent on IL-1 signaling  
All three knockout strains of mice (IFN, IL-1RI and IL-23p19) were susceptible to H. pylori 
infection and were colonized to the same extent as wild-type mice. Sublingually immunized 
IFNγ-/- and wild-type mice were protected against H. pylori infection and were able to reduce 
their bacterial load significantly when compared with unimmunized infected mice (Fig. 7A, 
paper II). Additionally, the bacterial load continued to remain low in sublingually immunized 
IFNγ-/- mice 5 weeks post-challenge. (Fig. 7D, paper II). Remarkably, sublingually immunized 
IFNγ-/- mice administered IL-17A neutralizing antibody in vivo after challenge with H. pylori 
bacteria were not protected with increased bacterial load in the stomach compared to 
sublingually immunized mice receiving isotype control antibody (paper II).  
In sublingually immunized IL-1RI-/- mice, protection against H. pylori infection was affected by 
the absence of IL-1 signaling (Fig. 7B, paper III). Even though the bacterial load in the stomach 
was decreased in sublingually immunized IL-1RI-/- mice compared to unimmunized mice, it was 
significantly higher than sublingually immunized wild-type mice (Fig. 7B, paper III). 
Sublingually immunized IL-23p19-/- mice had a statistically significant decrease in bacterial load 
in the stomach compared to unimmunized infected mice, and the reduction was similar to that 
seen in sublingually immunized wild-type mice compared to unimmunized infected mice (Fig. 
7C, paper III).  
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Figure 7. Bacterial load in the stomach of mice, post-challenge in 
sublingually immunized IFN-/-, IL-1RI-/- and IL-23p19-/- mice. Mice 
were immunized via SL route with H. pylori lysate antigens and CT (SL) 
or left unimmunized (Inf) and then challenged with live H. pylori bacteria. 
Two-three weeks post-challenge mice were evaluated for protection in A. 
IFNγ-/- mice, B. IL-1RI-/- mice, C. IL-23p19-/- mice and D. IFNγ-/- mice at 5 
weeks post-challenge. Stomach tissue was evaluated for H. pylori 
colonization by quantitative culture and expressed as log10 values of 
bacteria per stomach. Data are shown as mean values and standard error of 
mean (SEM) with A. n=5-7 mice/group; three independent experiments B. 
n=4-5 mice/group; pool of two experiments C. n=5-7 mice/group; pool of 
two experiments and D. n=5 mice/group; single experiment. Statistically 
significant difference in bacterial load between groups was assessed by 
unpaired two-tailed t-test with Welch correction and denoted by * 
(p<0.05), ** (p<0.01), *** (p<0.001) and ns (non-significant). 
 
Role of cytokines IFN and IL-17A in promoting inflammation in the stomach of sublingually 
immunized mice   
Since IFNγ, IL-1 and IL-23 have been associated with inflammation and/or IL-17A responses, 
we evaluated the influence of these cytokines on the immune response in the stomach and post-
immunization gastritis. Histopathology, saponin extracts for cytokine analysis and gene 
expression in the stomach was analyzed. The results showed that sublingually immunized IFNγ-/- 
mice had decreased inflammation in the stomach, but increased IL-17A secretion compared to 
sublingually immunized wild-type mice (Table 3, paper II). The already low inflammation score 
could be further dampened even more when neutralizing IL-17A antibody was administered in 
vivo to sublingually immunized IFNγ-/- mice (paper II). Sublingually immunized IL-1RI-/- mice 
also showed a decrease in inflammation score and the IL-17A and IFNγ gene expression was 
also decreased compared to sublingually immunized wild-type mice (Table 3, paper III). 
Furthermore, sublingually immunized IL-23p19-/- mice had a decrease in inflammation score, 
compared to that of sublingually immunized wild-type mice (Table 3, paper III). Considering the 
role of IL-23 in maintaining IL-17A responses, the IL-17A secretion in the stomach of 
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sublingually immunized IL-23p19-/- was unexpectedly not impaired and was instead similar 
compared to sublingually immunized wild-type mice (paper III). The sublingually immunized 
IL-23p19-/- mice instead had an increased secretion of IFNγ compared to sublingually 
immunized wild-type mice (paper III). Taken together, after SL immunization, these results 
indicate that IFNγ and IL-1 signaling is important for inducing inflammation in the stomach 
while IL-23 appears to play a minor.  
 
Table 3. Inflammation score after sublingual immunization in cytokine gene deficient mice 
 H. pylori lysate antigens + CT Infection control 
IFNγ-/- 2.86 ± 1.04* 0.08 ± 0.08 
WT 6.70 ± 1.25** 0.10 ± 0.10 
IL-1RI-/- 3.46 ± 2.03 0.38 ± 0.13 
WT 7.69 ± 1.76** 0.19 ± 0.09 
IL-23p19-/- 5.50 ± 2.84 0.70 ± 0.34 
WT 10.33 ± 2.21** 0.55 ± 0.05 
 
§ Inflammation score in stomachs of sublingually immunized or unimmunized mice post-challenge with live H. 
pylori bacteria. Data represents mean values ± SEM with n=4-9 mice /group (figure 7). Statistically significant 
difference between group scoring values for immunized mice compared to unimmunized infected mice was assessed 
by unpaired two-tailed t-test with Welch correction denoted *(p<0.05) and ** (p<0.01).  
 
Neutralization of IL-17A in the sublingually immunized IFN-/- mice post-challenge also showed 
that IL-17A is important for reduction of bacterial load in the stomach following SL 
immunization. However this IL-17A production in vivo is independent of IL-23 while partially 
dependent on IL-1 signaling.  
 
Cellular and antibody responses are intact in the absence of IFNγ, IL-23 and IL-1 signaling 
Cellular proliferative responses from MLN and spleen cells and subsequent levels of cytokines in 
in vitro culture supernatants were evaluated in sublingually immunized wild-type and knockout 
mice. MLN and spleen cells were isolated from the respective groups of mice and stimulated in 
vitro with H. pylori lysate antigens and proliferative response as well as the cytokine production 
in culture supernatants were measured. Sublingually immunized mice deficient for IFNγ, IL-23 
or IL-1 signaling showed no impairment in proliferative responses of MLN or spleen cells in 
vitro which were comparable to those of sublingually immunized wild-type mice (paper II and 
III). However, despite a strong proliferative response, IL-17A secretion was decreased in culture 
supernatants from MLN and spleen cells from sublingually immunized IL-1RI-/- and IL-23p19-/- 
mice compared to sublingually immunized wild-type mice (paper III). These results suggest that 
in spite of a vigorous proliferative response against H. pylori lysate antigens, IL-17A secretion is 
affected in the MLN cells from mice in the absence of IL-1 signaling, or IL-23, but not IFNγ. 
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In conclusion, the results from papers II and III showed that SL immunization is more efficient 
in reducing bacterial colonization of H. pylori in than IG immunization using H. pylori lysate 
antigens and CT as a vaccine. In addition, SL immunization induces increased IL-17A secretion 
in the stomach. Furthermore, we could also show that the IL-17A response was important for 
bacterial reduction while IFNγ promoted post-immunization gastritis. Finally, vaccine-induced 
IL-17A responses and reduction in bacterial load, post-challenge could be seen in the absence of 
IFNγ or IL-23. However, an intact IL-1 signaling was important for induction of IFN and IL-
17A responses in the stomach and reduction in bacterial load post-challenge.  
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APPENDIX I 
Evaluation of dmLT and CT adjuvants administered via the SL or IG route of 
immunization 
Previous results presented in this thesis have provided knowledge about the vaccine-induced 
immune response after SL and IG immunization but they were evaluated post-challenge long 
after the immunization event. We were thus interested in the early priming of the immune 
responses in the draining lymph nodes after immunization. As DCs are among the first cell type 
to come into contact with the antigen and adjuvant, we evaluated the effect of contact with of the 
two adjuvants CT and dmLT on DC activation and the ability of DCs in the CLN (for SL 
immunization) and MLN (for IG immunization) to prime T cell proliferation and cytokine 
secretion after immunization using H. pylori lysate antigens and CT or dmLT. Finally, to localize 
the IL-17A response in the stomach we also quantitated the IL-17A staining in the stomach of 
sublingually and intragastrically immunized mice when CT or dmLT was used as an adjuvant.   
 
Adjuvants dmLT and CT induce expression of genes related to activation and co-stimulation 
in DCs  
To address the contribution of the adjuvants in the priming of the T cell response in the draining 
lymph nodes, we first compared the effect of CT and dmLT on DC activation. CD11c+ DCs were 
isolated using MACS beads from the spleen of mice injected with Flt3L-secreting melanoma and 
stimulated in vitro with 1 µg/ml each of CT or dmLT. DCs were collected after 5 hours of 
stimulation with the adjuvants and gene expression in the cells was evaluated by PCR array 
(Mouse Dendritic & Antigen Presenting Cell; SA Biosciences/Qiagen). The DCs upregulated 
activation markers such as CD80 and CD86 in the presence of 1 g/ml of CT or dmLT (1.5-2-
fold), compared to un-stimulated DCs (Table. 4). In addition, CXCL2 (10.8-fold) and 
thrombospondin-1 (TSP-1) (67-fold) were also highly upregulated after stimulation with CT and 
to a lesser extent after stimulation with dmLT (2-fold and 29-fold respectively) (Table 4). 
CXCL2 attracts neutrophils, while thrombospondin-1 is known to (i) activate TGFβ and (ii) 
promote angiogenesis by inhibiting vessel dilation [100, 112]. CT also induced upregulation of 
IL-6 greater than dmLT while dmLT induced higher levels of IFNγ transcription than CT in DCs 
(Table 4). In summary, compared to dmLT, CT induced elevated levels of specifically TSP-1, 
CXCL2 and IL-6 in DCs, whereas dmLT preferentially induced transcription of IFNγ. Validation 
of the PCR array results on selected genes (IL-6, IFNγ and CXCL2) was performed using in-
house primers and confirmed the results of the RT-PCR array (Data not shown). 
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Table 4: Gene expression in dendritic cells stimulated with adjuvant CT or dmLT 
Up-regulated genes   
Gene 1 µg CT 1 µg dmLT Responding cell 
CCR1  2.05 1.43 T cells 
CD80 2.03 1.54 T cells 
CD86 2.05 1.57 T cells 
CXCL2 (Mip-2α) 10.80 2.28 PMNs*, stem cells 
FcγR1 (CD64) 2.99 1.41 MØ, Monocytes 
IFNγ 3.47 4.81 MØ, T and B cells, NK cells 
IL-6 5.92 2.71 B cells, Neutrophils 
TSP-1 
(Thrombospondin-1) 67.23 29.07 
MØ, Endothelial cells, 
PMNs* 
Tnfsf11 (RANKL) 2.68 2.98 Osteoclast cells, Stromal cells 
*PMN = polymorphonuclear cells, MØ = Macrophages 
 
Fold-Change 
 
§ RT-PCR array on cultured DCs. The difference between housekeeping genes and the target gene (∆CT) was 
determined, and the relative expression was calculated using the formula 2∆CT. Values are then expressed as fold 
change compared to unstimulated DCs.    
 
Sublingual immunization induces enhanced secretion of IL-17A and IFN  in CLN T cells  
We next evaluated the induction of IL-17A and IFNγ responses in the draining lymph nodes after 
SL or IG immunization. To block the exit of lymphocytes during the experiment, FTY720 was 
injected i.p. on day 1 and then every 48 h for 8 days. On day 2 mice were sublingually and 
intragastrically immunized using adjuvants CT and dmLT together with H. pylori lysate 
antigens. On day 7 after the immunizations, CLN and MLN cells were isolated and stained for 
Flow cytometry analysis. Our preliminary results show that, when comparing the routes of 
immunization, both adjuvants induced a stronger IL-17A and IFNγ responses in CLN cells than 
in MLN cells (Fig. 8A-C). However, when the two adjuvants were compared, CT induced strong 
IL-17A and IFNγ immune responses from CLN cells after SL immunization while CT and dmLT 
were comparable in the induction of IL-17A and IFNγ immune responses from MLN cells after 
IG immunizations (Fig. 8A-C).  
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Appendix I. Figure 8. IL-17A and IFN responses in the lymph nodes after immunization 
Mice were administered FTY720 i.p. on day 0 and every 2 days and mice were immunized via the SL or IG route 
with H. pylori lysate antigen and CT or dmLT or unimmunized (day 1). Seven days post-immunization, mice were 
sacrificed and CLN was taken from sublingually immunized mice and MLN from intragastrically immunized mice 
and single cell suspension was prepared for Flow cytometric analysis. Cells were stimulated with PMA + ionomycin 
and then stained for live cells, CD3, CD4, IL-17A and IFNγ.  A. Flow cytometric analysis of IL-17A and IFNγ on 
cells gated on live, CD3+CD4+ cells. Percentage of Live CD3+CD4+IL-17A+ and Live CD3+CD4+IFNγ+ cells B. 
number of total Live IL-17A+ IFNγ+ cells in the lymph nodes after immunization. Bars represent mean with n=3-5 
mice/group; pool of two experiments. Statistically significant difference was assessed by unpaired two-tailed t-test 
with Welch correction and denoted * (p<0.05). 
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Dendritic cells isolated from MLN or CLN and pulsed with antigens and adjuvant CT induce 
enhanced CD4+ T cell proliferation  
 
To further evaluate the T cell priming at the two draining lymph nodes after SL or IG 
immunization, we next addressed the induction of T cell responses by DCs from CLN and MLN 
cells and the effect of the adjuvants CT and dmLT on proliferation of T cells and cytokine 
secretion. We setup the in vitro culture assay system by using a model antigen ovalbumin and 
responder T cells from ovalbumin T cell transgenic (OT-II) mice (Fig 9.A). DCs were isolated 
from CLN and MLN of Flt3L-producing melanoma-injected mice and stimulated in vitro with 
10-3 µg/ml of CT or dmLT together with ovalbumin or H. pylori lysate antigens (Fig. 9A, B). 
DCs were collected after four hours of stimulation and thoroughly washed. CD4+  T cells were 
either isolated from spleens of OT-II mice,  or from MLN of sublingually immunized mice 
challenged with H. pylori and were co-cultured with DCs pulsed with either 2 mg/ml ovalbumin 
or 20 g/ml H. pylori lysate antigens, respectively, with or without 10-3 µg/ml CT or dmLT 
adjuvants. Pulsed DCs and antigen-specific CD4+ T cells were co-cultured for 5 days and 
proliferative and cytokine responses were measured. The results showed that pulsing DCs 
isolated from either MLN or CLN with ovalbumin and adjuvants induced higher proliferative 
responses by the CD4+ T cells than with ovalbumin alone (Fig. 9A). There was a tendency for 
DCs from MLN pulsed with CT and ovalbumin to induce increased proliferation in CD4+ T 
cells, compared to DCs from CLN pulsed with CT and ovalbumin (Fig. 9A). No such difference 
was observed in the ability of DCs from either MLN or CLN pulsed with dmLT and ovalbumin 
to induce CD4+ T cell proliferation. The results from these initial experiments provided 
information on DC activation, the optimal concentration of adjuvants, and the time point for 
measurement of the cytokine responses. 
 
Using the conditions established for the proliferation of OT-II mice, priming of H. pylori-
specific T cell responses by DCs in the presence or absence of adjuvant was then addressed. Our 
preliminary results showed only minor differences in the CD4+ T cell proliferative response 
induced by DCs isolated from MLN or CLN when H. pylori lysate antigens with or without 
adjuvant are used for pulsing (Fig. 9B). However the data also showed that DCs pulsed in vitro 
with H. pylori antigens and CT induced a more effective proliferation of CD4+ T cells than DCs 
pulsed with H. pylori antigens and dmLT (Fig. 9B).  
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Appendix I. Figure 9. In vitro culture of DCs from MLN and CLN and proliferation of CD4+ T cells after 
exposure to H. pylori antigens 
Mice were injected s.c. with Flt3L secreting melanoma cells to increase the number of DCs. DCs were isolated from 
MLN and CLN and pulsed with A. 2 mg/ml Ovalbumin antigen or B. 20 µg H. pylori antigen with or without 10-3 
µg CT or dmLT for 4 h. A. CD4+ T cells from OT-II transgenic mice or B. CD4+ T cells from H. pylori infected 
mice were isolated and cultured together with pulsed DCs for 5 days. Thymidine incorporation was then measured 
and proliferation of CD4+ T cells determined. Data are shown as mean values of counts per minute in triplicate wells 
with standard deviation in one experiment. No statistical analysis was carried out on the data.   
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Sublingual and intragastric immunization with H. pylori lysate antigens induces an increase 
in IL-17A+ cells in the stomach 
As we observed an increased frequency of IL-17A secreting cells in CLN of sublingually 
immunized mice and in the stomach post-challenge, we hypothesized that cells induced in the 
CLN possibly migrate to the stomach after challenge with live bacteria to perform their effector 
functions. Thus, we quantitated the numbers of IL-17A+ cells in the stomach of sublingually and 
intragastrically immunized mice and unimmunized infection controls by immunohistochemistry. 
The IL-17A+ staining reside mainly in the corpus region with some additional scattered cells in 
the antrum region of the stomach (Fig. 10C). The IL-17A+ cells were located in the lamina 
propria and submucosa (Fig. 10C). There was a tendency for the mean percent stained area of IL-
17A to be higher in sublingually immunized compared to intragastrically immunized mice when 
using CT as adjuvant, although the difference was not statistically significant (Fig. 10A). When 
dmLT was used as adjuvant in the vaccine, the IL-17A+ staining in the stomach after H. pylori 
challenge was increased in intragastrically immunized groups compared to infection controls, 
although again the difference was not statistically significant (Fig. 10B). In summary, both SL 
and IG immunization induce IL-17A responses in the stomach after challenge with H. pylori.  
 
In summary, our results show that immunizing mice via the SL route with either CT or dmLT as 
adjuvant together with H. pylori lysate antigens tend to induce a higher CD4+ IL-17A response in 
the CLN compared to IG immunization in the MLN although the IL-17A staining pattern in the 
stomach tissue was similar in sublingually or intragastrically immunized mice. One reason for 
the lack of difference in the IL-17A staining pattern in the stomach of immunized mice 
compared to the infection controls could be that the source of IL-17A might be different. 
Experiments were carried to co-stain IL-17A+ cells with CD4. However, the two staining 
protocols (IL-17A and CD4) were incompatible and thus made it difficult to assess the source of 
the IL-17A in the tissue. The data also show that CT and dmLT have similar effects on activation 
and co-stimulatory molecule expression in DCs, which might explain the high proliferative 
response by CD4+ T cells in vitro and possibly in vivo.  
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Appendix I. Figure 10. IL-17A+ staining in the stomach of mice after challenge with H. pylori.  
Mice were immunized via the SL or IG route with H. pylori lysate antigens and CT (SL or IG) or dmLT (SL or IG) 
or left unimmunized (Inf) and then challenged with live H. pylori bacteria. Two weeks post-challenge the mice were 
sacrificed and the stomach tissue was taken for immunohistochemistry staining for IL-17A. IL-17A staining in mice 
immunized with A. CT or B. dmLT. C. Representative picture of IL-17A staining in the stomach (in green) and 
nuclear DAPI staining (in blue) and IL-17A isotype control. Data are shown as % stained area of IL-17A per 100 
µm2 area of stomach in individual mice with 5-8 mice/group, in pool of two independent experiments. Filled squares 
represent mice immunized with adjuvant CT and open squares represent mice immunized with adjuvant dmLT and 
filled circles unimmunized infection controls (Inf). No statistical significance was detected.   
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APPENDIX II  
 
IL-17A staining pattern in the stomach of H. pylori-infected individuals and its relation to 
inflammation score  
We could show in the H. pylori mouse model that IL-17A responses are increased upon 
vaccination and are associated with the decreased bacterial load seen in the stomach. However, 
the relevance of our results to the human H. pylori infection and disease is not known.  Human 
gastric cells and human gastric cell lines have been shown to secrete IL-17A in response to H. 
pylori antigens [96, 193-194]. In addition, increased IL-17A responses in the stomach of H. 
pylori-infected individuals have been reported [35, 98, 133, 194]. However, this has not been 
correlated to bacterial load or inflammation. Thus, our aim was to evaluate the IL-17A response 
in biopsies from H. pylori-infected individuals and to correlate this with inflammation. We 
analyzed in a small cohort of individuals the IL-17A response in the stomach and its relation to 
bacterial load and inflammation. 
 
Increased staining for IL-17A in the stomach of H. pylori-infected individuals 
Antrum and corpus gastric biopsies obtained from adult volunteers were stained for IL-17A by 
immunohistochemistry; a separate biopsy from the same individual was evaluated by a 
pathologist for inflammation score according to the Sydney system [175]. Biopsies were 
obtained from H. pylori-positive (Hp+) individuals with ongoing inflammation but no corpus 
atrophy, from H. pylori-positive individuals with corpus atrophy (Hp+ CA) and for control 
purposes from H. pylori-negative (Hp-) individuals [5]. IL-17A staining in the gastric mucosa 
was quantified in individual biopsies from the antrum and corpus, respectively and related to the 
inflammation score from the same individual. Corpus biopsies had increased IL-17A+ staining 
compared to antral biopsies from Hp+ individuals although the difference was not statistically 
significant. A tendency for increased IL-17A+ staining of corpus biopsies from Hp+ CA 
compared to Hp+ individuals was also observed (Fig. 11A,B). Histopathological evaluation of 
these biopsies revealed that an increase in IL-17A+ staining correlated with inflammation score 
in corpus biopsies (Fig. 11C). This relationship could not be observed for the antral biopsies. 
Thus, our analyses show that IL-17A is increased in gastric antral and corpus biopsies collected 
from H. pylori infected individuals, in particular from those with an ongoing inflammation in the 
corpus mucosa.  
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Appendix II. Figure 11. Increased IL-17A+ staining of stomach corpus biopsies from H. pylori infected 
individuals. 
Antral and corpus biopsies were obtained from H. pylori-negative (Hp-) individuals with non-inflamed mucosa, H. 
pylori-positive (Hp+) individuals and H. pylori-positive individuals with corpus atrophy (Hp+CA) which were 
stained for IL-17A. A. Data are shown as % stained area of IL-17A per µm2 of individual antral and corpus biopsies 
from Hp- (n=6), Hp+ (n=6) and Hp+CA (n=5) individuals in each group; antral and corpus biopsies have been taken 
from the same individual. Filled circles represent corpus biopsies and open circles represent antral biopsies B. Non-
parametric two-tailed Spearman correlation analysis between the % IL-17A stained area in the corpus and 
inflammation score in the same individual. A statistically significant correlation between increased IL-17A staining 
and inflammatory score was detected, meaning that those individuals with increased IL-17A staining had increased 
inflammation score in the corpus. C. Representative picture of IL-17A staining (in green) and DAPI nuclear staining 
(in blue) and IL-17A isotype control staining in the stomach biopsies. 
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Discussion 
Several mucosal routes of vaccination have been evaluated with different combinations of 
antigens and adjuvants reporting varying levels of protection against H. pylori infection. 
However, the most effective route for immunization against H. pylori infection and its impact on 
the immune responses is not known. This thesis has evaluated IG and SL route of mucosal 
immunization and the use of the adjuvants dmLT and CT. The work in the thesis has also 
addressed the role of IL-17A and IFNγ in the protective immune responses against H. pylori 
infection and post-immunization gastritis. Knowing the appropriate immune response necessary 
for eradication of H. pylori infection with minimal post-immunization gastritis is essential for the 
rational design of vaccine and for planning vaccination strategies in countries where H. pylori 
infection is highly prevalent in the children and adults.  
 
SL immunization with H. pylori lysate antigens and dmLT as a mucosal adjuvant was efficient in 
inducing immune responses and protection against H. pylori infection in mice. Notably the effect 
on immune responses was comparable to that of CT. CT and LT belong to the family of AB 
toxins and are strong mucosal adjuvants, but extremely toxic in humans. Non-toxic derivatives 
have been developed by introducing mutations in the A subunit which leads to attenuation of 
ADP-ribosylating activity and induction of intracellular cAMP. Protection against H. pylori 
infection after IG immunization has been reported in mice using two such derivatives, LTK63 
and mLT (R192G) [53, 74, 142, 210]. However, in humans, intranasal administration of the 
adjuvant LTK63 with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis 
antigens led to a serious side-effect called Bell´s palsy (facial paralysis). The use of the adjuvant 
in vaccines was discontinued indefinitely which was very discouraging for the field of mucosal 
vaccines [119]. The adjuvant mLT (R192G) have also been evaluated in humans together with 
inactivated H. pylori whole cell vaccine via the IG route. However the study reported diarrheal 
side-effects in volunteers that received the adjuvant with or without the inactivated bacteria [104] 
which again resulted in the adjuvant being discontinued for use in vaccines. Despite these 
drawbacks and with the ambition to find an alternative adjuvant, a new mutant of LT was 
constructed carrying a two mutations in the A1 subunit (dmLT), again with the aim of 
attenuating the ADP-ribosylating activity and minimizing the cAMP production [160]. The 
potential for dmLT to function as a mucosal adjuvant has been evaluated in mice using a 
lyophilized H. pylori whole-cell (HWC) vaccine proving to be efficient in reducing the live H. 
pylori bacterial load in the stomach of mice [210]. SL immunization with dmLT and a 
pneumococcal whole cell vaccine was shown to confer protection against pneumococci infection 
in mice [126]. Given the history of failures using detoxified enterotoxins as mucosal adjuvants, 
further studies of dmLT in larger clinical trials are warranted before it can be considered suitable 
for use in a mucosal vaccine particularly in children.   
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In our study we show that SL immunization with H. pylori antigens and dmLT induces strong H. 
pylori specific proliferative responses in MLN and spleen cells. This proliferative response was 
accompanied by an increase in IL-17A and IFNγ cytokine secretion by these cells which was 
comparable to when CT was used as an adjuvant in the vaccine. Further, SL immunization using 
either CT or dmLT together with H. pylori lysate antigens induced enhanced H. pylori-specific 
stomach IgA and serum IgG antibodies. In support of our findings, studies using dmLT together 
with H. pylori antigens, Enterotoxigenic E.coli (ETEC)-expressing colonization factors, Shigella 
spp. antigens or tetanus toxoid for IG or IN immunization, have confirmed that antigen-specific 
antibody responses are enhanced by dmLT as well as an IL-17A response in mice [80, 86, 160-
161, 183, 210]. In addition, the in vitro IL-17A response to the purified protein derivative (PPD) 
by peripheral blood mononuclear cells, from individuals vaccinated with Bacillus Calmette-
Guérin (BCG) can be enhanced by dmLT [113]. Importantly, in phase I clinical trials dmLT 
administered intragastrically to  volunteers  alone or in combination with an ETEC vaccine  was 
well tolerated ([61] and Lundgren et al Personal communication). Thus, the results presented in 
this thesis together with preclinical and phase I trials performed in volunteers suggests that 
dmLT is a safe non-toxic adjuvant with potential for use in human vaccines administered via the 
mucosal route. Remarkably, our preliminary data suggests that SL immunization with 
recombinant antigens from H. pylori together with dmLT confers protection against H. pylori 
infection (Paper I), making dmLT also a promising candidate mucosal adjuvant for inclusion in a 
H. pylori vaccine in humans. The safety issues regarding the translocation of components of 
adjuvants and bacteria through the olfactory bulb when immunizing via the IN route are not 
likely to occur if the SL or IG routes of vaccination were used. 
 
Several mechanisms have been proposed whereby dmLT is able to induce such strong mucosal 
immune responses which are comparable to using a highly toxic adjuvant, CT. The binding of 
CT to cells is mediated through  cholera toxin B subunit (CTB) binding to the GM1 ganglioside 
which is present on most nucleated cells [87]. The B subunit of LT also has the ability to bind to 
GM1 and some additional receptors [174]. Since dmLT is a derivative of the LT molecule, it is 
possible that it may bind to additional receptors compared to CTB. Also dmLT is known to 
induce low amounts of cAMP in host cells which may be sufficient for the adjuvant function but 
not for the toxicity [160]. It has been proposed that the ADP-ribosylation activity and adjuvant 
function of CT, LT or their derivatives are closely related [134, 184, 190]. However, the precise 
mechanism whereby dmLT performs its functions inside the host cells is largely unknown. Our 
preliminary data showed that dmLT can induce cytokine and chemokine gene expression such as 
IFNγ, CXCL2 and IL-6 in DCs, although to a somewhat lesser extent than CT, suggesting that 
dmLT is less pro-inflammatory than CT. However, it is interesting that the adjuvant functions of 
dmLT and CT are almost comparable despite their molecular differences in toxicity.  
 
Our studies have also focused on the evaluation of the IG and SL routes of immunization in 
protection against H. pylori infection. We report that both IG and SL routes of immunization 
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using H. pylori lysate antigens and CT induce significant reduction in the bacterial load in the 
stomach of mice. But the sublingually immunized mice had lower bacterial load in the stomach 
than intragastrically immunized mice. IG immunization is the route which has been extensively 
evaluated in the field of vaccine-induced protection against H. pylori infection which is not 
surprising as the bacteria colonizes in the stomach. Prophylactic or therapeutic IG route of 
vaccination using CT as adjuvant together with inactivated H. pylori whole-cell bacteria or lysate 
antigens, has been shown to provide protection against H. pylori infection and against reinfection 
in mice [163-164, 168, 181-183]. IG immunization in humans would be the obvious route of 
immunization as the stomach is the environment the bacteria first encounter. In addition a 
drinkable vaccine would be highly desirable due to the ease in administration to both children 
and adults. Furthermore needle-free vaccines reduce the risk associated with spreading disease 
through infected needles and the need of trained personal for administration of the vaccine, 
although a cold chain handling of the vaccine maybe required as it is for the Cholera vaccine, 
Dukoral®. Indeed, encouraging for the H. pylori vaccine field, based on preclinical studies in 
mice (203) a recent phase I clinical trial has shown that IG immunization using formalin-killed 
E.coli bacteria over-expressing colonization factors for ETEC and the hybrid binding subunit 
protein (LCTBA) generates strong mucosal and systemic antibody responses in human 
volunteers against ETEC [86, 127]. In humans, the IG immunization route has already been in 
use for a wide range of clinical trials with H. pylori antigens and mucosal adjuvants. As only 
antibody and not T cell responses were evaluated, the antibody titers in the volunteers cannot be 
correlated to the protective effects of the vaccine [216]. Despite the obvious advantages of the IG 
route of immunization for a H. pylori vaccine, there are some concerns regarding the stability of 
the antigen and adjuvants in the harsh acidic environment and the difficulty in determining the 
dose required for an effective immune response and protection against H. pylori infection. 
Furthermore, the studies have evaluated a single route of immunization and it is unknown 
whether the IG route is the most efficient in inducing immune responses against H. pylori. 
 
SL immunization has previously been reported to induce protection against H. pylori infection 
when CT and H. pylori lysate antigens have been used [182]. In addition, as mentioned 
previously, we report now that when dmLT and H. pylori lysate antigens were administered via 
the SL immunization route, bacterial loads were highly reduced, to the same extent as when CT 
was used. When comparing SL and IG route of immunization against H. pylori infection using 
CT and H. pylori lysate antigens, there was a tendency in our study and  in earlier reports [182] 
for the SL route of immunization to be more efficient in reducing bacterial load in the stomach 
than the IG route. This was particularly evident when dmLT was used with H. pylori lysate 
antigens [201] or when recombinant antigens HpaA and UreB and CT were used in the vaccine 
[69]. The difference in protection against H. pylori infection after SL and IG immunization 
reported in the two studies was statistically significant [69, 201]. The SL route of immunization 
is not confined to the H. pylori field of research, but has been used in administering vaccines 
against other mucosal infections in mice. For example, recently, SL immunization using 
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recombinant influenza virus hemagglutinin protein 1 (sHA1) and CT was shown to confer 
protection in mice against the pandemic influenza virus H1N1 and also induced antibody 
responses in mucosal and systemic tissues [196]. The SL mucosa is a site where small molecular 
weight drugs and molecules can be applied and transported rapidly via the blood stream, and 
more importantly the route is already used in humans. However, the mechanisms of lymphocyte 
recirculation after SL immunization are not completely defined and the ability to induce immune 
responses at other mucosal sites in humans is not known. 
 
In addition to evaluating the bacterial load in mice after immunization via SL and IG route, we 
also evaluated the inflammation and cytokine responses generated against H. pylori infection. It 
has previously been reported that both IG and intranasal immunization using H. pylori lysate 
antigens and CT induce inflammation in the stomach post-challenge referred to as post-
immunization gastritis in mice [72, 77, 213]. As inflammation is generally associated with 
protection, it introduces a problem when proceeding to clinical trials [72, 77]. However, at least 
in mice it has been shown that when the infection is cleared the post-immunization gastritis will 
subside. [72]. When comparing post-immunization gastritis after challenge, intragastrically 
immunized mice had a lower inflammation score in the stomach compared to SL immunized 
mice. However, in the stomach, only IL-17A was elevated in intragastrically immunized mice 
while both IFNγ and IL-17A were elevated in sublingually immunized after challenge with live 
bacteria.  
 
In our preliminary experiments we could show that SL immunization increased the number of 
CD4+ T cells secreting IL-17A+ and IFN+ in the CLN compared to the number of CD4+ T cells 
secreting IL-17A+ and IFN+ cells in MLN after IG immunization. Surprisingly, the IL-17A 
secretion and staining in the stomach was comparable in intragatrically and sublingually 
immunized mice, suggesting that post-challenge CD3+CD4+IL-17A+-producing cells are 
expanded in the MLN (Paper II) that migrate to the stomach. Taken together, our preliminary 
data suggests that there is a bias for priming IL-17A and IFN in CLN than in MLN. However, it 
is possible and not tested in the current study, if repeated immunizations would induce IL-17A 
responses in the MLN.  
 
Previous studies evaluating the role for IFNγ in vaccine-induced protection against H. pylori 
infection in mice have unfortunately generated indecisive results [12, 71]. Our data showed that 
sublingually immunized IFNγ-/- mice had a similar reduction in bacterial load compared to 
immunized wild-type mice. Interestingly, similar to our observations in sublingually immunized 
IFNγ-/- mice, the intranasal route of immunization using H. pylori lysate antigens and CT in 
IFNγ-/- mice also results in reductions in bacterial load. Our study also confirms previous 
observations that in vivo neutralization of IFNγ after SL immunization had no effect on the 
bacterial reduction against H. pylori [68]. In addition, the SL immunized IFNγ-/- mice also had 
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lower level of inflammation in the stomach compared to immunized wild-type mice, indicating 
instead a pivotal role for IFNγ in inflammation. Although IFNγ has been shown to have a 
protective role in intracellular bacterial infections, for example, in Mycobacterium and 
Salmonella infections [70] a dominant role in protection against extracellular pathogens might be 
questioned. Instead, considering the known functions of IL-17A at mucosal sites (see next 
section), it is possible that IL-17A alone can fight extracellular infections. Indeed, susceptibility 
to chronic mucocutaneous candidiasis in humans is associated  with a deficiency in IL-17A 
responses which further confirms the protective role of IL-17A in extracellular mucosal 
infections [48]. The sublingually immunized IFNγ-/- mice had elevated levels of IL-17A in the 
stomach compared to immunized wild-type mice and similar bacterial load suggesting that IL-
17A can lower the bacterial numbers in the stomach. In agreement with our results, a recent 
study in mice deficient in Th1 responses (IL-12p35-/-) showed that immunization via the 
intranasal route, resulted in increased IL-17A responses in the stomach and  protection against H. 
pylori infection [56].  
 
When IL-17A was neutralized in SL immunized IFNγ-/- mice post-challenge, bacterial load was 
increased to the level of unimmunized infected mice. These results suggest a role for IL-17A in 
bacterial reduction after SL immunization. The role of IL-17A in protection after IG 
immunization in IFNγ-/- mice however, has not yet been addressed. That IL-17A may play a 
pivotal role in the anti-bacterial response may  not be surprising considering the many effects of 
IL-17A on the immune system including, recruitment of neutrophils and inducing anti-microbial 
peptide production by epithelial cells [101]. In addition IL-17A has also been shown to be 
important for induction of IgA responses [32, 83]. Since IL-17A was only neutralized at the time 
of challenge the effects can be quite different from lacking IL-17A at the time of immunization 
and through the entire experiment. Thus we wanted to further study importance of IL-17A during 
the priming phase of the immune response in inducing immune responses and protection against 
H. pylori infection. This was addressed by using knockout mice lacking cytokines IL-1 and IL-
23 that are important in the induction or maintenance of IL-17A responses [25, 219]. We could 
have utilized IL-17A-/- mice; but, when we initiated the study it was already reported that 
intranasally immunized IL-17A-/- mice are protected against H. pylori infection [51]. Although 
not discussed in the article, we found that in IL-17A-/- mice intranasally immunized with H. 
pylori lysate antigens and CT elevated levels of IL-17F which may compensate for the lack of 
IL-17A as they bind to the same receptor and have overlapping functions ([118] and unpublished 
observations). Thus we chose to use IL-23p19-/- mice that lack the cytokine important for the 
maintenance of IL-17A+ cells. IL-23p19-/- mice were first described to be resistant to 
experimental autoimmune encephalomyelitis (EAE) which is known to be promoted by IL-17A-
secreting CD4+ T cells. In humans, IL-1β is important together with IL-6 and IL-23 in the 
induction of IL-17A responses [3, 141, 223, 225]. During H. pylori infection, IL-1β, IL-23, IL-
17A and IFNγ have been shown to be elevated in the stomach of H. pylori infected individuals 
compared to uninfected individuals indicating that the conditions necessary for the polarization 
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of the T cell response to IL-17A production are present in H. pylori infected individuals [21, 35, 
65, 124, 194, 203].  
 
IL-23 has been shown to play an important role in promoting intestinal inflammation in a T cell 
transfer model of colitis as IL-23R-/- mice and IL-23p19-/- mice were resistant to colitis 
development [10, 218]. Previous studies on colonization of H. pylori SS1 in IL-23p19-/- mice 
have reported a slightly higher bacterial load and reduced inflammation 3-4 month post-infection 
[88]. However, when we initiated our study, the role of IL-23 in maintaining vaccine-induced IL-
17A responses was unknown. Sublingually immunized IL-23p19-/- mice were able to reduce the 
bacterial load to a similar extent as sublingually immunized wild-type mice. These mice also had 
IL-17A and IFNγ production in the stomach, to a similar extent as sublingually immunized wild-
type mice. Although this was a surprising observation, studies in the T cell transfer model of 
colitis in IL-23p19Rag1 double knockout mice have shown that IL-17A can be secreted by T 
cells in the intestine during inflammation despite the lack of IL-23 [10, 90]. Thus in the stomach 
and colon, IL-23 may be dispensable for the maintenance of IL-17A responses. Indeed, a recent 
study also presented findings similar to our own showing that intranasally immunized IL-23p19-/- 
were protected against H. pylori infection albeit with a low level of IL-17A gene expression the 
stomach [56]. In the SL immunized IL-23p19-/- mice, protection against H. pylori infection was 
associated with a lower inflammation score in the stomach compared to SL immunized wild-type 
mice. There have been studies suggesting that IL-23 can drive a pathogenic Th17 population 
[90], and that in the absence of IL-23, a preferential IL-10 producing Th17 population develops 
[146]. In addition, IL-23 has been shown to block regulatory T cell expansion which might 
further suggest a role for the IL-23 to generate a pathogenic immune responses [9]. We have not 
evaluated in our studies the IL-10 production in the stomach of sublingually immunized IL-
23p19-/- mice, but this would be of interest as the non-pathogenic Th17 cells may be the 
protective against H. pylori infection.  
 
IL-1β has been shown to be essential for the induction of IL-17A responses to co-administered 
antigen using CT as an adjuvant [84]. Our studies showed that SL immunization was less 
efficient in reducing the bacterial load in IL-1RI-/- mice, suggesting an important role for IL-1β 
signaling in vaccine-induced protection against H. pylori infection. The requirement for IL-1β 
signaling has also been observed in mice after IG immunization in vaccine-induced protection 
against H. pylori infection [84]. The same study also showed that IFNγ and IL-17A gene 
expression was disturbed in the stomach of vaccinated IL-1RI-/- mice. As both IFNγ and IL-17A 
responses were reduced in the stomach of IL-1RI-/- mice the higher colonization in the 
sublingually immunized mice may be due to either reduced IFN or reduced IL-17A. However, 
as we have seen that protection after SL immunization was not dependent on IFN we believe 
that the reduced protection that we observe the stomach of IL-1RI-/- mice may be due to a defect 
in IL-17A secretion. IL-1β signaling has also been shown to be critical for the development of 
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Th17 cells in an EAE mouse model in which IL-1RI-/- mice were shown to be resistant to the 
development of EAE with a greatly reduced number of CD4+ T cells secreting IL-17A in the 
brain lesions [211]. One caveat to using IL-1RI-/- mice, to study the role of this cytokine in 
protection against H. pylori infection is that the adjuvant functions of CT might be impaired in 
these mice. Thus it cannot be ruled out, that the reduced protection we see in SL immunized IL-
1RI-/- mice might be due to an impaired adjuvant activity of CT in the absence of IL-1β. We have 
addressed this possibility by studying the immune responses in the wild type and IL-1RI-/- mice 
after SL immunization with H. pylori antigens alone or H. pylori antigens and CT before 
challenge with live bacteria. We observed no difference in H. pylori-specific serum IgG response 
but a reduction in H. pylori-specific IgA responses in SL immunized IL-1RI-/- compared to wild-
type mice. Our results suggest that, as discussed previously, the adjuvant function of CT is 
necessary for protection against H. pylori infection and that it may be mediated through IL-1β 
during immunization.  
 
Our studies in mice have suggested a role for IL-17A in protection and to a lesser extent in 
inflammation against H. pylori infection. The role of IL-17A in human H. pylori infection is only 
now beginning to be elucidated. Two elegant studies comparing the IL-17A responses in the 
stomach of children (>10 years) and adults have shown that lesser gastritis in H. pylori infected 
children is associated with less IL-17A responses compared to H. pylori infected adults that had 
a higher IL-17A secretion in the stomach and increased gastritis score. These association studies  
in H. pylori infected individuals suggest that IL-17A might be pro-inflammatory [95, 195]. Co- 
staining of IL-17A and bacteria or neutralization of IL-17A in H. pylori-infected individuals and 
its impact on bacterial load and inflammation might give a clue as to whether IL-17A is indeed 
pro-inflammatory. Thus, when designing a vaccine for human use, it is important to keep in mind 
that children and adults may respond differently to the vaccine with respect to the IL-17A 
response and the efficacy may therefore be different, if the IL-17A response is protective.  
 
Concluding remarks 
The focus in this thesis has been to elucidate immune mechanisms of vaccine-induced protection 
against H. pylori infection with emphasis on the role of IL-17A and IFNγ using the mouse model 
of H. pylori. An essential point to be considered in our studies is that mice are not men and it 
remains to see if the results in this study hold true when evaluated in humans. Possible 
differences in the anatomy and cellular composition of the mucosal compartment can lead to 
different outcomes for the immune response generated [147]. In particular, the function of IL-
17A responses that we report in mice remains to be confirmed in humans. Nevertheless, we 
could show in our preliminary study that the frequency of IL-17A+ cells was elevated in the 
stomach of H. pylori-infected individuals and particularly in those with corpus atrophy and 
higher inflammation score. The IL-17A may also come from other sources than CD4+ T cells and 
it would therefore be of interest to evaluate the stomach for innate sources of IL-17A to 
determine to what extent they may be important for the protection or inflammation. Another 
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important function of Th17 cells is the production of IL-22 which induces anti-microbial 
peptides and acts, together with IL-17A, on the epithelial cells and it would be of interest to 
evaluate IL-22 in relation to protection and inflammation [120].  
 
In summary, our results show that dmLT is a strong mucosal adjuvant that induces similar 
immune responses and most importantly, protection against H. pylori infection in mice 
comparable to the gold standard adjuvant, CT. Its pre-clinical and clinical use so far has 
established that dmLT would be a good candidate for inclusion in a human vaccine. Furthermore, 
the SL route of immunization has proven in mouse studies to generate strong mucosal and 
systemic immune responses together with protection against H. pylori infection. The SL route is 
already in use in humans, although not for vaccination against bacterial pathogens and thus 
evaluation of the SL route for induction of mucosal immune responses in humans is needed. Our 
studies suggest that a key feature of the SL route of immunization seems to be the generation of 
IL-17A and IFN responses against H. pylori infection (Fig 12). The IL-17A and IFN responses 
may be induced in the absence of IL-23 but requires IL-1 signaling. The mechanisms of 
protection and post-immunization gastritis may be separated in that IL-17A is important for 
protection while IFNγ promotes inflammation (Fig 12).  
 
The results from the work presented in this thesis provide a basis for the design of an appropriate 
clinical trial with a H. pylori vaccine in humans. The recommendation based on our work would 
be to use a combination of recombinant antigens such as HpaA, UreA or UreB together with the 
mucosal adjuvant, dmLT. The SL route of immunization could be considered since it has also 
been proven safe in humans and to induce immune responses in the stomach at least in mice. As 
a comparison, we also recommend the IG route of immunization as reference.  
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Figure 12. Summary of series of events in mice after sublingual vaccination. 1. SL immunization with H. pylori 
lysate antigens and CT followed by challenge with live H. pylori bacteria. 2. The bacteria will relocate close the 
epithelium in the stomach where bacterial antigens can either be sampled by DCs or secreted by the bacteria which 
will activate the PPRs in the epithelium, tissue resident macrophages and DCs. This will also induce influx of a few 
neutrophils and macrophages through epithelial secretion of CXCL8. 3. DCs will migrate to the draining lymph 
node with the sampled antigens. 4. In the lymph node, expansion of B cells with T cell help will occur resulting in 
formation of germinal centers, antibody production and isotype switching. 5. DCs will present the sampled antigen 
to primed CD4+ T cells that will recognize H. pylori antigens presented on MHC-II and expansion of T cells occur. 
DCs will secrete cytokines such as IL-6, IL-12, IL-23, IL-1β, TNFα and IFN that will further differentiate the T 
cells into IL-17A and IFNγ producing cells. In our studies, we have also addressed the role of cytokine IL-1β and 
IL-23 and evaluated their impact on IL-17A responses. 6. Due to the ongoing infection, T and B cells will be 
recruited back to the stomach via the efferent lymph guided by homing receptors. 7-8. In the stomach, production of 
IL-17A and IFN will occur which will further lead to activation of macrophages, influx of neutrophils and antibody 
production. 9. These series of events will result in bacterial reduction and to some extent inflammation. Our results 
in the IFN-/- mice showed that post-immunization gastritis is attenuated and neutralization of IL-17A abrogates the 
protection. We believe that, in H. pylori infection induced post-immunization gastritis; we have been able to 
separate the protective effects of inflammation from the pro-inflammatory.  
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